November 9-12, 2021
Boston, USA

www.ctad-alzheimer.com
Email: ctad@ant-congres.com
SUMMARY

Organizing & Scientific Committees 3
Lifetime Achievement Award 4
Keynotes 5
Scientific program 7
Onsite Poster presentations 20
CTAD Venue 30
Sponsors 31
CTAD Organizing Committee

Jacques Touchon MD, PhD
University of Montpellier
France

Paul Aisen MD
Alzheimer’s Therapeutic Research Institute (ATRI)
University of Southern California (USC), San Diego, USA

Bruno Vellas MD, PhD
University Hospital of Toulouse
France

Mike Weiner MD
University of California
San Francisco (UCSF)
USA

CTAD Scientific Committee

Susan ABUSHAKRA (San Francisco, USA); Paul AISEN (San Diego, USA); Rebecca E. AMARIGLIO (Boston, USA); Sandrine ANDRIEU (Toulouse, France); Randall J. BATEMAN (St. Louis, USA); Kaj BLENNOW (Molndal, Sweden); Merce BOADA (Barcelona, Spain); Marc CANTILLON (Livingston, USA); Maria CARRILLO (Chicago, USA); Suzanne CRAFT (Winston-Salem, USA); Steven DEKOSKY (Miami, USA); Rachelle DOODY (Basel, Switzerland); Bruno DUBOIS (Paris, France); Howard FELDMAN (San Diego, USA); Nick FOX (London, UK); Giovanni B. FRISONI (Brescia, Italy); Serge GAUTHIER (Montreal, Canada); Michael GRUNDMANN (San Diego, USA); Harald HAMPEL (Woodcliff Lake, USA); Oskar HANSSON (Lund, Sweden); Tobias HARTMANN (Hamburg, Germany); Takeshi IWATSUO (Tokyo, Japan); Frank JESSEN (Cologne, Germany); Ara KHACHATURIAN (Washington DC, USA); Zaven KHACHATURIAN (Washington DC, USA); Yan LI (St. Louis, USA); Jorge J. LLIBRE GUERRA (St. Louis, USA); Constantine G. LYKETOS (Baltimore, USA); Gad A. MARSHALL (Boston, USA); José Luis MOLINUEVO (Barcelona, Spain); Ronald PETERSEN (Minneapolis, USA); Craig W. RITCHIE (Edinburgh, UK); Robert RISSMAN (San Diego, USA); Marwan SABBAGH (Las Vegas USA); Stephen SALLOWAY (Providence, USA); Rachel SCHINDLER (New York, USA); Philip SCHELTENS (Amsterdam, NL); Lon SCHNEIDER (Los Angeles, USA); Eric SIEMERS (Philadelphia, USA); Yong SHEN (Heife, China); Jiong SHI (Las Vegas, USA); Reisa SPERLING (Boston, USA); Yaakov STERN (New York, USA); Jacques TOUCHON (Montpellier, France); Christopher H. VAN DYCK (New Haven, USA); Bruno VELLAS (Toulouse, France); Michael W. WEINER (San Francisco, USA); Bengt WINBLAD (Stockholm, Sweden); Jin-Tai YU (Shanghai, China)
This year the Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research is awarded to Ron Petersen, MD, Ph.D., in recognition for his extensive contributions to the advancement of AD clinical trials.

Ronald C. Petersen, MD, PhD - Professor of Neurology and Director of the Mayo Alzheimer’s Disease Research Center, Mayo Clinic, Rochester, MN (USA).

Dr. Ronald C. Petersen received a Ph.D. from the University of Minnesota and graduated from Mayo Medical School in 1980. He completed an internship in Medicine at Stanford University Medical Center and returned to the Mayo Clinic to complete a residency in Neurology. That was followed by a fellowship in Behavioral Neurology at Harvard University Medical School/Beth Israel Hospital in Boston, Massachusetts. Dr. Petersen was named the Cora Kanow Professor of Alzheimer’s Disease Research and Mayo Clinic Distinguished Investigator in 2011. He is currently the Director of the Mayo Alzheimer’s Disease Research Center and the Mayo Clinic Study of Aging and has authored over 1000 peer-reviewed articles on memory disorders, aging, and Alzheimer’s disease. Dr. Petersen has received the 2004 MetLife Award for Medical Research in Alzheimer’s Disease and the 2005 Potamkin Prize for Research in Picks, Alzheimer’s and Related Disorders of the American Academy of Neurology. In 2012 he received the Khachaturian Award and the Henry Wisniewski Lifetime Achievement Award in 2013 from the Alzheimer’s Association. In 2011 he was appointed by the Secretary of Health and Human Services to serve as the Chair of the Advisory Committee on Research, Care and Services for the National Alzheimer’s Disease Plan.
“Anti-Tau Drug Development for Alzheimer’s Disease and Other Tauopathies”
Adam Boxer, MD, PhD
Endowed Professor in Memory and Aging, University of California, San Francisco (UCSF), USA
Dr. Boxer directs UCSF’s Neurosciences Clinical Research Unit and the Alzheimer’s Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program at the UCSF Memory and Aging Center. Dr. Boxer’s research is focused on developing new treatments and biomarkers for neurodegenerative diseases, particularly those involving tau and TDP-43. Dr. Boxer received his medical and doctorate degrees as part of the NIH-funded Medical Scientist Training Program at New York University Medical Center. He completed an internship in Internal Medicine at California Pacific Medical Center, a residency in Neurology at Stanford University Medical Center, followed by a fellowship in behavioral neurology at UCSF. He is the principal investigator (PI) of the Advancing Research and Treatment for FTLD (ARTFL) Rare Disease Clinical Research Consortium, a collaborative project funded by the National Institutes of Health to create an 18-center North American research network to support the development of new therapies for FTLD. He also leads the Four Repeat Tauopathy Neuroimaging Initiative (4RTNI), a multicenter, longitudinal tau PET and biomarker study focused on PSP and CBD.

“Vascular Risk Factors and Alzheimer’s Disease: Implications for Clinical Trials”
Cynthia Carlsson, MD, MS
Professor in Alzheimer’s Disease, Division of Geriatrics and Gerontology, University of Wisconsin, Madison, WI (USA)
Dr. Carlsson is a geriatrician at the William S. Middleton Memorial Veterans Hospital in Madison, Wisconsin, where she treats veterans with dementia and memory issues. She is the Clinical Core leader and a co-leader for the Biomarker Core in the Wisconsin ADRC. She also serves as director of the Wisconsin Alzheimer’s Institute. Dr. Carlsson’s research focuses on the effects of vascular risk factors and their treatments on cognition and biomarkers for Alzheimer’s disease in persons at risk for dementia. Vascular risk factors in midlife, such as high cholesterol and elevated blood pressure, have been associated with an increased risk of developing Alzheimer’s disease decades later. It is unknown, however, whether treating vascular risk factors will reduce the risk of dementia.
Keynotes

“Biostatistics in Alzheimer’s Disease Therapeutic Trials: A Future of Convergence”
Rema Raman, PhD

Rema Raman, PhD
Professor of Neurology, Keck School of Medicine, University of Southern California and Director of Biostatistics at USC Alzheimer Therapeutic Research Institute, San Diego, CA (USA)

Rema Raman is a Professor of Neurology at the University of Southern California (USC) and the Director of Biostatistics at USC’s Alzheimer’s Therapeutic Research Institute. She also serves as the Biostatistics Unit lead and Recruitment Unit co-lead for the National Institute of Health funded Alzheimer Clinical Trials Consortium. Dr. Raman has extensive experience as a biostatistician and clinical trialist, providing biostatistics and data management leadership and support to the design, coordination, conduct and analyses of clinical trials in Alzheimer’s disease, acute stroke, post-traumatic stress disorder, and traumatic brain injury. Her statistical research interests are in efficient clinical trial design and analysis, centralized statistical monitoring and data visualization, recruitment and retention and missing and longitudinal data analysis topics. Dr. Raman is committed to the effective teaching of biostatistics and clinical trial methodology and is the co-director of the National Institute on Aging and Alzheimer’s Association funded Institute of Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD).

“Therapeutic Trials in Alzheimer’s Disease: A New Hope for 2022?”
Ronald C. Petersen, MD, PhD

Ronald C. Petersen, MD, PhD
Professor of Neurology and Director of the Mayo Alzheimer’s Disease Research Center, Mayo Clinic, Rochester, MN (USA)

Dr. Ronald C. Petersen received a Ph.D. from the University of Minnesota and graduated from Mayo Medical School in 1980. He completed an internship in Medicine at Stanford University Medical Center and returned to the Mayo Clinic to complete a residency in Neurology. That was followed by a fellowship in Behavioral Neurology at Harvard University Medical School/Beth Israel Hospital in Boston, Massachusetts. Dr. Petersen was named the Cora Kanow Professor of Alzheimer’s Disease Research and Mayo Clinic Distinguished Investigator in 2011. He is currently the Director of the Mayo Alzheimer’s Disease Research Center and the Mayo Clinic Study of Aging and has authored over 1000 peer-reviewed articles on memory disorders, aging, and Alzheimer’s disease. Dr. Petersen has received the 2004 MetLife Award for Medical Research in Alzheimer’s Disease and the 2005 Potamkin Prize for Research in Picks, Alzheimer’s and Related Disorders of the American Academy of Neurology. In 2012 he received the Khachaturian Award and the Henry Wisniewski Lifetime Achievement Award in 2013 from the Alzheimer’s Association. In 2011 he was appointed by the Secretary of Health and Human Services to serve as the Chair of the Advisory Committee on Research, Care and Services for the National Alzheimer’s Disease Plan. 
CTAD 2021

Program at a glance

- **Tuesday, NOVEMBER 9**

  4.00 p.m  PROGRAM ONSITE in Boston & LIVESTREAMED on the digital platform

  4.00 p.m  Opening Ceremony and CTAD Lifetime Achievement Award

  4.15 p.m  KEYNOTE 1: Therapeutic Trials in Alzheimer’s Disease: A New Hope for 2022?

  4.35 p.m  ROUNDTABLE 1: The FDA accelerated approval of aducanumab: a panel discussion

  5.05 p.m  SYMPOSIUM 1: Recent advances in plasma biomarkers to improve preclinical and prodromal AD trials

  5.45 p.m  Networking time and receptions

- **Wednesday, NOVEMBER 10**

  8.00 a.m  PROGRAM ONSITE in Boston & LIVESTREAMED on the digital platform

  8.00 a.m  KEYNOTE 2: Anti-Tau Drug Development for AD and Other Tauopathies

  8.20 a.m  ROUNDTABLE 2: New hope in translational research for Alzheimer drug development

  8.50 a.m  ORAL COMMUNICATIONS

  9.50 a.m  Coffee break and poster session

  10.20 a.m  LATE BREAKING READOUT ROUNDTABLE 4

  11.20 a.m  ORAL COMMUNICATIONS

  12.05 p.m  Lunch

  1.20 p.m  SYMPOSIUM 2: TRAILBLAZER-ALZ: Three Clinical Trials of Donanemab in Early Alzheimer’s Disease

  2.20 p.m  KEYNOTE 4: Biostatistics in Alzheimer’s Disease Therapeutic Trials: A Future of Convergence

  2.40 p.m  ORAL COMMUNICATIONS

  3.40 p.m  Coffee break and poster session

  4.10 p.m  ROUNDTABLE 7: Value-Generating Exploratory Trials in Neurodegenerative Dementias

  4.40 p.m  ORAL COMMUNICATIONS

  5.10 p.m  LATE-BREAKING READOUT ROUNDTABLE 8

  5.40 p.m  Networking time and receptions

- **Thursday, NOVEMBER 11**

  8.00 a.m  ONSITE PROGRAM LIVE STREAMED to the digital platform

  8.00 a.m  KEYNOTE 3: Vascular Risk Factors and AD: Implications for Therapeutic Trials

  8.20 a.m  ORAL COMMUNICATIONS

  9.50 a.m  Coffee break and poster session

  10.20 a.m  ORAL COMMUNICATIONS

  11.35 a.m  LATE-BREAKING READOUT ROUNDTABLE 6

  12.05 p.m  Lunch

  1.20 p.m  ORAL COMMUNICATIONS

  2.20 p.m  KEYNOTE 4: Biostatistics in Alzheimer’s Disease Therapeutic Trials: A Future of Convergence

  2.40 p.m  ORAL COMMUNICATIONS

  3.40 p.m  Coffee break and poster session

  4.10 p.m  ROUNDTABLE 7: Value-Generating Exploratory Trials in Neurodegenerative Dementias

  4.40 p.m  ORAL COMMUNICATIONS

  5.10 p.m  LATE-BREAKING READOUT ROUNDTABLE 8

  5.40 p.m  Networking time and receptions

- **Friday, NOVEMBER 12**

  8.00 a.m  ONSITE PROGRAM LIVE STREAMED to the digital platform

  8.00 a.m  SYMPOSIUM 4: Metabolomics a Biochemical Roadmap for Drug Discovery in Alzheimer’s Disease

  8.40 a.m  ORAL COMMUNICATIONS

  10.40 a.m  Coffee break and poster session

  11.10 a.m  ORAL COMMUNICATIONS

  12.10 p.m  Lunch break

  1.10 p.m  SYMPOSIUM 5: Diversity in Alzheimer’s Disease Clinical Trials

  1.50 p.m  ORAL COMMUNICATIONS

  3.20 p.m  Statistics workshop: re-thinking trial outcomes

All times are USA Eastern Standard Time
All sessions to be held in the Grand Ballroom A at Mezzanine Level
Tuesday, NOVEMBER 9

PROGRAM ONSITE in Boston & LIVESTREAMED on the digital platform

4.00 p.m
Opening Ceremony and CTAD Lifetime Achievement Award Alzheimer’s Disease Therapeutic Research
Presented to Ronald C. Petersen, MD, PhD, in recognition for his extensive contributions to the science and therapeutics of Alzheimer’s Disease
Introduction by Paul Aisen, Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA (USA), Jacques Touchon, Montpellier University, Montpellier (France), Bruno Vellas, Gerontopole, Toulouse University, Toulouse (France), Mike Weiner, UCSF, San Francisco, CA (USA)

4.15 p.m
KEYNOTE 1
Therapeutic Trials in Alzheimer’s Disease: A New Hope for 2022?
Ronald C. Petersen, Mayo Alzheimer’s Disease Research Center, Mayo Clinic, Rochester, MN (USA)

4.35 p.m
ROUNDTABLE 1
The FDA accelerated approval of aducanumab: a panel discussion
Paul Aisen, Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA (USA), Maria Carrillo, Alzheimer’s Association, Chicago, IL (USA), Jason Karlawish, University of Pennsylvania, Philadelphia, PA (USA), Gil Rabinovici, University Of California San Francisco - San Francisco (USA)

5.05 p.m
SYMPOSIUM 1
Recent advances in plasma biomarkers to improve preclinical and prodromal AD trials
Chair: Kaj Blennow, University Of Gothenburg - Gothenburg (Sweden)
Measuring Blood Based Biomarkers of Alzheimer’s Disease for Clinical Trials
Jeffrey L. Dage, Research Fellow; Eli Lilly and Company, Indianapolis, IN (USA)
Blood plasma measures of Aβ, tau, and NfL species for screening and use in clinical trials of Alzheimer’s disease
Randall J. Bateman, Washington University School of Medicine, St. Louis, MO (USA)
Diagnostic and prognostic algorithms based on blood biomarkers for use in clinical trials
Oskar Hansson, Lund University, Lund (Sweden)

5.45 p.m
Networking time and receptions

All times are USA Eastern Standard Time
All sessions to be held in the Grand Ballroom A at Mezzanine Level
PROGRAM ONSITE in Boston & LIVESTREAMED on the digital platform

**Wednesday, NOVEMBER 10**

**8.00 a.m**
**KEYNOTE 2**
Anti-Tau Drug Development for AD and Other Tauopathies
Introduction: Mike Weiner, University of California San Francisco, UCSF, San Francisco, CA (USA)
Adam Boxer, University of California at San Francisco, San Francisco, CA (USA)

**8.20 a.m**
**ROUNDTABLE 2**
New hope in translational research for Alzheimer drug development
Chair: Dennis Selkoe, Brigham and Women’s Hospital, Boston, MA (USA)
Discussants: Kirk Daffner, Brigham and Women’s Hospital, Boston, MA (USA), Stephen Salloway
Brown Medical School and Warren Alpert Medical School of Brown University, Providence, RI (USA)

**8.50 a.m**
**ORAL COMMUNICATIONS**
Chairs: Rachelle Doody, F. Hoffmann, La Roche - Basel (Switzerland), Lon Schneider, Keck School of Medicine, USC, Los Angeles, CA (USA)

**OC1** - Evoke and evoke+: two phase 3 trials investigating oral semaglutide in participants with early Alzheimer’s disease
Philip Scheltens 1, Alireza Atri 2, 3, Howard H. Feldman 4, Kristine Brown Frandsen 5, Stephen C. Gough 5, Filip Krag Knop 6, Pernille Poulsen 3, Lars Lau Raket 3, Mary Sano 7, Hilkka Soininen 9, Jeffrey Cummings 9
1 Alzheimer Center, Amsterdam University Medical Center, Amsterdam (The Netherlands), 2 Banner Sun Health Research Institute - Sun City, AZ (USA), 3 Brigham & Women’s Hospital and Harvard Medical School – Boston, MA (USA), 4 Harvard Medical School, Harvard University, Boston, MA - University Of California, CA (USA), 5 Novo Nordisk A/S - Søborg (Denmark), 6 Herlev And Gentofte Hospital, University of Copenhagen - Copenhagen (Denmark), 7 Icahn School Of Medicine at Mount Sinai - New York, NY (USA), 8 University of Eastern Finland - Kuopio (Finland), 9 University Of Nevada - Las Vegas, NV (USA)

OC2 - Plasma GFAP is an early marker of Aβ but not tau pathology in Alzheimer’s disease
Joana Pereira 1, Shonara Janelidze 2, Ruben Smith 2, Mattsson-Carlsgren Niklas 2, Sebastian Palmqvist 2, Charlotte Teunissen 3, Henrik Zetterberg 1, Erik Stromrud 2, Nicholas Ashton 1, Kaj Blennow 2
1 Lund University - Lund (Sweden), 2 Lund University - Lund (Sweden), 3 Amsterdam University Medical Centers - Amsterdam (Sweden), 4 Sahlgrenska University Hospital - Sahlgrenska University Hospital (Sweden)

**9.05 a.m**
**OC3** - Phase 1 trial design for ACU193, a monoclonal antibody that selectively binds soluble Abeta oligomers
Eric Siemers 1, Janice Hitchcock 1, Karen Sundell 1, James Senetar 1, Robert Dean 1, Jasna Jerecic 2, Ericka Cline 2, Kent Iverson 2, Kathleen Powell 2, Jerry Moore 3, Deven Dandekar 3, Chris Edgar 3, Richard Manber 4, Nicolco Fuin 5, Russell Barton 4
1 Acumen Pharmaceuticals - Carmel (USA), 2 Acumen Pharmaceuticals - Charlottesville (USA), 3 Cogstate Ltd. - Melbourne (Australia), 4 Ixico Plc - London (United Kingdom)

**9.20 a.m**
**OC4** - Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease (StoMP-AD): Methodology for a Randomized, Double-Blind, Placebo-Controlled Phase II Trial
Miranda E. Orr 1, 2, Mitzi M. Gonzales 3, Valentina R. Garbarino 4, Eduardo M. Zilli 5, Ronald C. Peterson 5, James L. Kirkland 6, Tamara Tekhonia 4, Nicolas Musi 1, 2, Sudha Seshadri 3, 4, Suzanne Craft 1
1 Wake Forest School Of Medicine, Gerontology And Geriatric Medicine, Wake Forest Alzheimer’s Disease Research Center - Winston-Salem (USA), 2 Wake Forest School Of Medicine, Gerontology And Geriatric Medicine, Wake Forest School Of Medicine, Winston-Salem (USA), 3 University Of Texas Health Science Center At San Antonio, Glenn Biggs Institute For Alzheimer’s And Neurodegenerative Diseases, Department Of Neurology - San Antonio (USA), 4 University Of Texas Health Science Center At San Antonio, Glenn Biggs Institute For Alzheimer’s And Neurodegenerative Diseases, Department Of Neurology - San Antonio (USA), 5 Mayo Clinic, Department Of Neurology, Mayo Clinic Alzheimer’s Disease Research Center, The Mayo Clinic Study Of Aging - Rochester (USA), 6 Mayo Clinic, Department Of Neurology, Mayo Clinic Alzheimer’s Disease Research Center, The Mayo Clinic Study Of Aging - Rochester (USA), 7 Barshop Institute for Longevity and Aging Studies and Geriatric Research, Education and Clinical Center - San Antonio (USA), 8 Boston University School of Medicine, Department of Neurology - Boston (USA)
Wednesday, NOVEMBER 10

9.50 a.m  ROUNDTABLE 3
Digital Therapeutics for Mild Cognitive Impairment: New Pathway to Treatment
Chair: Murali Doraiswamy, Duke University - Durham, NC (USA)
Discussants: Jeffrey Shuren, Food & Drug Administration - Silver Spring, MD (USA), Rhoda Au, Boston University - Boston, MA (USA), James R. Williams, Biogen Digital Health - Cambridge, MA (USA)

10.20 a.m  Coffee break and poster session (Statler room)

10.50 a.m  LATE-BREAKING READOUT ROUNDTABLE 4
Phase 2 Trial of Semorinemab in Mild-to-Moderate Alzheimer’s Disease (Lauriet): Topline results
Chair: Rachelle Doody, Hoffmann-La Roche Ltd. Basel (Switzerland)
Discussants: Cecilia Monteiro, Genentech, Inc South San Francisco, CA (USA), Randall Bateman, Washington University - St. Louis, MO (USA), Stephen Salloway, Brown University Medical School - Providence, RI (USA), Adam Boxer, University of California San Francisco, UCSF, San Francisco, CA (USA)

11.20 a.m  ORAL COMMUNICATIONS
Chairs: John Alam, EIP Pharma, Boston, MA (United States), Jacques Touchon, University of Montpellier, Montpellier (France)

11.20 a.m  OC5 - Effects of the oral p38α kinase inhibitor neflamapimod on motor function (gait) in patients with mild-to-moderate dementia with Lewy bodies (DLB)
John Alam 1, Hui-May Chu 2, Kelly Blackburn 3
1Eip Pharma, Inc - Boston (USA), 2Anoixis Corporation - Natick (USA)

11.35 a.m  OC6 - Access to Alzheimer’s Disease Participant Level Results Data Via Data Sharing Platforms
Rebecca Li 1, 2, Murali Doraiswamy 3, Ida Sim 1, 4, Lon Schneider 4
1Vivli, Inc, Cambridge, MA (USA), 2Harvard Medical School, Center for Bioethics, Boston, MA (USA), 3Duke University School of Medicine, Durham, NC (USA), 4University of California, San Francisco (USCF), San Francisco, CA (USA), 5Keck School of Medicine of the University of Southern California, Los Angeles, CA (USA)

11.50 a.m  OC7 - Phase 2/3 trials of ATH-1017, a novel treatment for mild-to-moderate Alzheimer’s disease: Updates and baseline data
Xue Hua 1, Kevin Church 1, Kai-Bin Ooi 1, Joyce Maalouf 1, William Walker 1, Charles Bernick 1, Sam Dickson 3, Suzanne Hendrix 3, Larry Ereshefsky 4, Hans J Moebius 5
1Athira Pharma, Inc - Bothell, WA (USA), 2Department Of Neurology, University Of Washington - Seattle, WA (USA), 3Pentara Corporation - Millcreek, Ut (USA), 4Follow The Molecule: Cns Consulting Llc - California (USA), 5Athira Pharma, Inc. - Bothell Wa (USA)

12.05 p.m  Lunch* (ABC Room) and Poster Session (Statler Room)

1.20 p.m  SYMPOSIUM 2
TRAILBLAZER-ALZ: Three Clinical Trials of Donanemab in Early Alzheimer’s Disease
Chair: John R. Sims, Eli Lilly & Company, Indianapolis, IN (USA)

TRAILBLAZER-ALZ study: Amyloid clearance results in a rapid and sustained reduction in plasma P-tau217 levels
John R. Sims, MD, PhD, Eli Lilly & Company, Indianapolis, IN (USA)

TRAILBLAZER-ALZ 2 Baseline Characteristics and Screening Data
Paul Solomon, PhD, Boston University Alzheimer’s Disease Center, Boston, MA (USA)

TRAILBLAZER-ALZ 3 Trial Design and Rationale
Pierre Tariot, MD, Banner Alzheimer’s Institute, Phoenix, AZ (USA)

*for attendees who pre-purchased lunch
2.00 p.m  LATE-BREAKING READOUT ROUNDTABLE 5
Assessment of the Clinical Effects of Lecanemab, the Correlation of Plasma Aβ 42/40 Ratio With Changes in Brain Amyloid PET SUVr, and Safety from the Core and Open Label Extension of the Phase 2 Proof-of-Concept Study, BAN2401-000-201, in Subjects With Early Alzheimer’s Disease
Chair: Jeffrey Cummings, University Of Nevada - Las Vegas, NV (USA)
Discussants : Christopher Van Dyck1, Randall Bateman 2, Chad Swanson 3
1Yale University School of Medicine - New Haven, CT (USA), 2Washington University - St. Louis, MO (USA), 3Eisai Inc. - Woodcliff Lake, NJ (USA)

2.30 p.m  ORAL COMMUNICATIONS
Chairs: Suzanne Schindler, Washington University - St. Louis, MO (USA), Mathieu Ceccaldi, University Hospital of Marseille, Marseille (France)
2.30 p.m  OC8 - Results of a Phase 2 Study of AR1001 in Mild to Moderate Alzheimer’s disease Patients
David R. Greeley 1, James Rock 2, Vijay Hingorani 2, Fred Kim 2, Matthew Choung 3
1Northwest Neurological, Spokane, WA (United States), 2Aribio Usa, Inc. - San Diego (USA), 3Aribio Co., Ltd. · Seongnam (Republic of Korea)

2.45 p.m  OC9 - Binding profiles to different amyloid-beta species of lecanemab, aducanumab and gantenerumab, the three most developed antibodies for Alzheimer’s disease
Lars Lannfelt 1, Malin Johannesson 1, Patrik Nygren 2, Linda Söderberg 2, Christer Möller 2
1Uppsala University · Uppsala (Sweden), 2Bioarctic · Stockholm (Sweden)

3.00 p.m  OC10 - A Polymorphism Cluster at the 2q12 locus May Predict Response to Piromelatine in Patients with Mild Alzheimer’s Disease
Lon Schneider 1
1University Of Southern California - Department of Psychiatry and The Behavioral Sciences, and Department of Neurology, Keck School Of Medicine, and Leonard Davis School Of Gerontology of The University of Southern California, Los Angeles, CA (USA)

3.15 p.m  OC11 - Impact of Cocoa Flavanols and Multivitamins on Cognitive Function: Findings COSMOS-MIND
Laura Baker 1, Joann Manson 2, 3, Stephen Rapp 1, Howard Sesso 1, Sarah Gaussoin 1, Sally Shumaker 1, Mark Espeland 1
1Wake Forest School Of Medicine · Winston Salem (USA), 2Brigham & Women’s Hospital · Boston (USA), 3Harvard Medical School · Boston (USA)

3.30 p.m  OC12 - Recruiting the Innate Immune System to Treat Mild-to-Moderate Alzheimer’s Disease: Short-Term, Double-Blind, Placebo-Controlled Phase II Trial Shows that GM-CSF/Sargramostim Treatment Leads to Improvements in MMSE and Blood Biomarkers of Neuropathology/Neurodegeneration (Aβ, Tau, and UCH-L1)
Huntington Potter 1, Jonathan Woodcock 1, Timothy Boyd 2, Christina Coughlan 1, John O’shaughnessy 1, Manuel Borges 1, Ashesh Thaker 1, Balaibail Raj 1, Katarzyna Adamszuk 1, David Scott 4, Vanesa Adame 1, Paige Anton 1, Heidi Chial 1, Joseph Daniels 1, Helen Gray 1, Michelle Stocker 1, Stefan Sillau 1
1University Of Colorado Alzheimer’s And Cognition Center · Aurora (USA), 2Partner Therapeutics · Lexington (USA), 4University Of South Florida · Tampa (USA), 3Bioclinica · Princeton (USA)

3.45 p.m  ROC9 - Performance of the PrecivityAD™ blood test in detection of brain amyloidosis in cognitively normal and cognitively impaired individuals
Suzanne Schindler 1, Kevin Yarasheski 1, Tim West 2, Matthew Meyer 2, Kris Kirmess 2, Anne Fagan 1, John Morris 1, Randall Bateman 3
1Washington University · St. Louis, MO (USA), 2C2n Diagnostics · St. Louis, MO (USA), 3Washington University · St. Louis, MO (USA)
4:30 p.m. SYMPOSIUM 3
Bringing Repurposed Drugs to Market: Challenges and Opportunities from Research to Commercialization
Chair: Howard Fillit, Alzheimer’s Drug Discovery Foundation – New York, NY (USA)

Repurposing Riluzole for Mild Alzheimer’s Disease
Ana Pereira, Icahn School of Medicine At Mount Sinai - New York, NY (USA)

Towards a Phase III Trial of Rotigotine in Combination with Cholinesterase Inhibitors in Patients with Alzheimer’s Disease
Giacomo Koch, Fondazione Santa Lucia - Rome (Italy)

Low-dose Levetiracetam for Treatment of Age-related Cognitive Impairment and to Delay Progression of Alzheimer’s Dementia
Michela Gallagher, Agenbio – Baltimore, MD (USA)

5:10 p.m. Networking time and receptions
Thursday, NOVEMBER 11

ON SITE PROGRAM LIVE STREAMED TO THE DIGITAL PLATFORM

8.00 a.m KEYNOTE 3
Vascular Risk Factors and AD: Implications for Therapeutic Trials
Introduction: Jacques Touchon, University of Montpellier, Montpellier (France)
Cynthia M. Carlson, University of Wisconsin School of Medicine and Public Health, Madison, WI (USA)

8.20 a.m ORAL COMMUNICATIONS
Chairs: Sandrine Andrieu, INSERM Unit Toulouse University, Toulouse (France), Paul Aisen, ATRI at USC, San Diego, CA (USA)

8.20 a.m OC13 - Targeted medication therapy management can successfully augment cognitive reserve in predementia Alzheimer’s disease: Results from the Intervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer’s Symptomatic Expression (INCREASE) Study
Gregory Jicha 1, Erin Abner 1, Frederick Schmitt 1, Lynne Eckmann 1, Mark Huffman 1, Ashley Martinez 1,2, Brooke Beech 1,2, Rosmy George 1, Riham El Khouli 1, Doaa Ali 1, Daniela Moga 1
1University Of Kentucky - Lexington (USA), 2Harvard Medical School - Boston (USA), 3Washington State University - Pullman (USA)

8.35 a.m OC14 - A model combining tau PET, baseline cognition and neurofilament light optimally predicts
Ruben Smith 1, Nicholas Cullen 1, Antoine Lezuy 1, Shorena Janelidze 1, Sebastian Palmqvist 1, Niklas Mattsson-Carlsgren 1, Oskar Hansson 1
Lund University - Lund (Sweden)

8.50 a.m ORAL COMMUNICATIONS: FOCUS ON BIOMARKERS IN AD
Chairs: Kathryn Papp, Massachusetts General Hospital, Brigham & Women’s Hospital - Boston, MA (USA), Mike Weiner, UCSF, San Francisco, CA (USA)

8.50 a.m LB1 - Plasma pTau231 as an early marker of amyloid-β pathology for preclinical Alzheimer’s disease trial selection
Nicholas Ashton 1, Marta Milà-Alomà 2, Andrea Benedet 1, Thomas Karikari 1, José Luis Molinuevo 2, Eugeen Vanmechelen 1, Henrik Zetterberg 1, Marc Suárez-Calvet 2, Kaj Blennow 1
1Gothenburg University - Göteborg (Sweden), 2Barcelona Beta - Barcelona (Spain), 3Adx Neuroscience - Ghent (Belgium)

9.05 a.m LB2 - Association of emerging beta-amyloid and tau pathology with early cognitive changes in clinically normal older adults
Michelle Farrell 1, Kathryn Papp 1, Rachel Buckley 2, Heidi Jacobs 1, Aaron Schultz 1, Michael Properzi 1, Patrizia Vannini 2, Bernard Hanseuw 1, Dorene Rentz 2, Keith Johnson 2, Reisa Sperling 2
1Massachusetts General Hospital - Boston (United States), 2Massachusetts General Hospital, Brigham & Women’s Hospital - Boston (United States)

9.20 a.m LB3 - AlzoSure® Predict, a simple, non-invasive blood test to predict the early onset of Alzheimer’s disease with the ability to identify MCI patients, before the clinical symptoms are identifiable [in the same test] 6 years in advance of clinical diagnosis
Simona Piccirella 1, Leander Van Neste 2, Christopher Fowler 2, James Doecke 2, Daniela Uberti 3, Paul Kinnon 1
1Diadem Srl - Brescia (Italy), 2Halixo Bv - Altenaken (Belgium), 3The Florey Institute Of Neuroscience And Mental Health -Parkville (Australia), 4The Australian E-Health Research Centre - Herston (Australia), 5Department Of Molecular And Translational Medicine, University Of Brescia - Brescia (Italy)

9.35 a.m LB4 - Introduction of plasma biomarker screening for the AHEAD 3-45 Study
Reisa Sperling 1, Keith Johnson 2, Jin Zhou 3, Michael C. Irizarry 3, Shobha Dhadda 3, Lynn D. Kramer 3, Chad J. Swanson 3, Yarasheski Kevin 1, Robert A. Rissman 5, Paul S. Aisen 6
1Brigham And Women’s Hospital, Massachusetts General Hospital, Harvard Medical School - Boston (United States), 2Eisai - San Francisco (United States), 3C 2 N Diagnostics - St. Louis (United States), 4University Of California San Diego, University Of Southern California - San Diego (United States), 5Paul S. Aisen 6

9.50 a.m Coffee break and poster session (Statler Room)
Thursday, NOVEMBER 11

10.20 a.m  ORAL COMMUNICATIONS

Chairs: Laura Baker, Wake Forest School of Medicine, Winston-Salem, NC (USA), Stephen Salloway, Brown University Medical School - Providence, RI (USA)

10.20 a.m  LB5 - Efforts to improve recruitment and engagement of underrepresented populations in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Study

Miriam T. Ashford 1, Ozioma Okonkwo 2, Monica Rivera Mindt 1, Rema Raman 4, Garrett Miller 4, Michael C. Donohue 4, Godfrey A. Coker 4, Rachel L. Nosheny 5, Ronald C. Petersen 6, Paul S. Aisen 4, Michael Weiner 7

1. Northern California Institute For Research And Education (ncire), Department Of Veterans Affairs Medical Center - San Francisco (United States), 2Wisconsin Alzheimer’s Disease Research Center And The Department Of Medicine, University Of Wisconsin School Of Medicine And Public Health - Madison (United States), 3Psychology & Latin American Latino Studies Institute, Fordham University, Joint Appointment In Neurology, 4Mahn School Of Medicine At Mount Sinai - New York (United States), 5Alzheimer’s Therapeutic Research Institute, University Of Southern California - San Diego (United States), 6Department Of Psychiatry, University Of California San Francisco - San Francisco (United States), 7Department Of Neurology, Mayo Clinic - Rochester (United States), 8Department Of Radiology And Biomedical Imaging, University Of California San Francisco - San Francisco (United States)

10.35 a.m  LB6 - LM11A-31 small molecule p75 receptor modulator – phase 2a randomized placebo-controlled safety and exploratory endpoint trial in mild-moderate Alzheimer’s disease

Frank Longo 1, Taylor Schmitz 2, Hayley Shanks 3, Eric Reiman 3, Kewei Chen 4, Stephen Massa 4, Manfred Windisch 5

1. Pharmatrophix - Menlo Park (United States), 2Western University - London (Canada), 3Banner Alzheimer’s Institute - Phoenix (United States), 4UCSF And SFVamc - San Francisco (United States), 5Neurosocios - Graz (Austria)

10.50 a.m  LB7 - The cost-effectiveness of aducanumab and donanemab for early Alzheimer’s disease in the United States

Eric Ross 1, 2, 3, Marc Weinberg 1, 2, 3, Steven Andre 4, 5, Deborah Blacker 1, 6

1. Department Of Psychiatry, Massachusetts General Hospital - Boston (United States), 2Department of Psychiatry, McLean Hospital - Belmont (United States), 3Department of Psychiatry, Harvard Medical School - Boston (United States), 4Department Of Neurology, Massachusetts General Hospital - Boston (United States), 5Department of Neurology, Harvard Medical School - Boston (United States), 6Department of Epidemiology, Harvard T.H. Chan School of Public Health - Boston (United States)

11.05 a.m  LB8 - Ketones improve functional connectivity and apparent fiber density in the dorsal attention network: direct links to improved attention and brain energetics in mild cognitive impairment

Maggie Roy 1, Manon Edde 1, Mélanie Fortier 1, Valérie St. Pierre 1, Christian Bocti 1, Tamas Fulop 1, Maxime Descoteaux 1, Stephen Cunnane 1

1. Université De Sherbrooke - Sherbrooke (Canada)

11.20 a.m  LB9 - Consistency of Efficacy Assessments Across Various Statistical Methods from the Lecanemab Phase 2 Proof-of-Concept Study, BAN2401-000-201, in Subjects With Early Alzheimer’s Disease

Shobha Dhadda 1, Michio Kanekiyo 1, Michio Kanekiyo 1, David Li 1, Chad Swanson 1, Michael Irizarry 1, Donald Berry 2, Scott Berry 2, Lynn Kramer 1

1. Eisai Inc. - Woodcliff Lake (United States), 2Berry Consultants, LLC - Austin (United States)

11.35 a.m  LATE-BREAKING READOUT ROUNDTABLE 6

Top-line Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease

Chairs: Michael Detke, Cortexyme, South San Francisco, CA (USA), Marwan Sabbagh, Barrow Neurological Institute, Dignity Health/St Joseph’s Hospital and Medical Center, Phoenix, AZ (USA)

Michael Detke 1, Marwan Sabbagh 2, Mark Ryder 1, Joanna Bolger 1, Dave Hennings 1, Vladimir Skljarevski 1, Shirin Kapur 1, Debasish Raha 1, Florian Ermini 1, Mai Nguyen 1, Ursula Haditsch 1, Kim Perry 1, Kelly Ritch 1, Suzanne Hendrix 1, Sam Dickson 1, Haticke Hasturk 1, Sarah Horine 1, Craig Mallinckrodt 1, Leslie Holsinger 1, Casey Lynch 1, Stephen Dominy 1

1. Cortexyme - South San Francisco, CA (USA), 2Barrow Neurological Institute, Dignity Health/St Joseph’s Hospital and Medical Center, Phoenix, AZ (USA), 3UCSF - San Francisco, CA (USA), 4Innovative Analytics - Portage, MI (USA), 5Datafy Clinical R&D - Portage, MI (USA), 6Pentara Corporation - Millcreek, UT(USA), 7Forsyth Institute - Cambridge, MA (USA)
12.05 p.m  Lunch* (ABC Room) and Poster Session (Statler Room)  
*for attendees who pre-purchased lunch

12.00 p.m  ORAL COMMUNICATIONS
Chairs: Samuel Dickson, Pentara Corporation, Salt Lake City, UT (USA), Bruno Vellas, University of Toulouse, Gerontopole, Toulouse (France)

12.00 p.m  OC15 - Flortaucipir in the Trailblazer-ALZ trial
Sergey Shcherbinin 1, Ming Lu 2, Amanda Morris 3, Ixavier Higgins 1, Cynthia Evans 1, Albert Lo 1, Emily Collins 1,2, John Sims 1, Dawn Brooks 1, Mark Mintun 1,2  
1Eli Lilly And Company - Indianapolis (USA), 2Avid Radiopharmaceuticals - Philadelphia (USA)

1.35 p.m  OC16 - Effect of racial differences in Alzheimer disease biomarkers on design and analysis of prevention trials
Chengjie Xiong 1, Tammie Benzinger 1, Suzanne Schindler 1, Anne Fagan 1, Jason Hassenstab 1, John Morris 1  
Washington University (USA)

2.20 p.m  KEYNOTE 4  
Biostatistics in Alzheimer’s Disease Therapeutic Trials: A Future of Convergence  
Introduction: Paul Aisen, Alzheimer Therapeutic Research Institute, San Diego, CA (USA)  
Rema Raman, Keck School of Medicine, University of Southern California and Director of Biostatistics at USC Alzheimer Therapeutic Research Institute, San Diego, CA (USA)

2.40 p.m  ORAL COMMUNICATIONS
Chairs: Cindy Carlsson, University of Wisconsin, Madison, WI (USA), Adam Boxer, University of California San Francisco, UCSF, San Francisco, CA (USA)

2.40 p.m  OC19 - SEMA4D blocking antibody, pepinemab, is a novel potential treatment for neurodegenerative disease: clinical proof of concept in HD supports clinical development in AD  
Terrence Fisher 1, Elizabeth Evans 1, Alisha Reader 1, Vikas Mishra 1, Crystal Mallow 1, Ernest Smith 1, John Leonard 1, Andrew Feigin 2, Eric Siemens 3, Janet Wittes 4, Maurice Zauderer 1  
1Vaccinex - Rochester (USA), 2For The Huntington Study Group And Signal Investigators And Coordinators - Rochester (USA), 3Siemens Integration Llc - Indianapolis (USA), 4For Statistics Collaborative - Washington (USA)

3.10 p.m  OC21 - Dyadic enrollment in a phase 3 mild cognitive impairment clinical trial
Navneet Hakhu 1, Daniel Gillen 1, Josh Grill 1  
University Of California, Irvine - Irvine (United States)
Thursday, November 11

3.25 p.m  OC22 - PIONEER, a Phase 2 Study to Evaluate Treatment with T3D-959 in Patients with Mild to Moderate Alzheimer's Disease: Study Design and Update
John Didsbury 1, Warren Strittmatter 1, Jessica Stanek 1, Stanley Chamberlain 1, Blake Swearingen 1, Hoda Gabriel 1
T3d Therapeutics, Inc. - Research Triangle Park (United States)

3.40 p.m  Coffee break and poster session (Statler Room)

4.10 p.m  ROUNDTABLE 7
Value-Generating Exploratory Trials in Neurodegenerative Dementias
Moderator: Howard Fillit, MD, Alzheimer's Drug Discovery Foundation, New York, NY (USA)
Discussants: Jeffrey Cummings, MD, Chambers-Gundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV), NV (USA), Michael Gold, MD, Vice President, Development Neurosciences, AbbVie, Deerfield, IL (USA), Suzanne Hendrix, PhD, President and CEO, Pentara Corporation, Salt Lake City, UT (USA)

4.40 p.m  ORAL COMMUNICATIONS
Chairs: Rema Raman, Alzheimer Therapeutic Research Institute, San Diego, CA (USA), Pierre-Jean Ousset, Gerontopole University of Toulouse Hospital, Toulouse (France)

4.40 p.m  OC23 - Comparison of the FCSRT and RBANS in screening for early AD clinical trials: Enrichment for disease progression
Edmond Teng 1, Paul Manser 1, Nan Hu 1, Monarch Shah 1, Karen Pickthorn 1, Mira Blendstrup 1, Giuliana Faccin 1, Susanne Ostrowitzki 1, Kaycee Sink 1
1Genentech, Inc. - South San Francisco (USA), 2F. Hoffmann-La Roche Ltd. - Basel (Switzerland)

5.10 p.m  LATE-BREAKING READOUT ROUNDTABLE 8
Dose and time dependent changes in plasma ptau181 in patients treated with aducanumab in the ENGAGE and EMERGE trials
Chair: Stephen Salloway, Brown Medical School and Warren Alpert Medical School of Brown University, Providence (USA)
Presenter: Oskar Hansson, Lund University - Lund (Sweden)
Panel members: Jeffrey Cummings, University Of Nevada Las Vegas (UNLV) - Las Vegas (United States), Gil Rabinovici, University Of California San Francisco - San Francisco (United States)

5.40 p.m  Networking time and receptions
Friday, NOVEMBER 12

ONSITE PROGRAM LIVE STREAMED TO THE DIGITAL PLATFORM

8.00 a.m SYMPOSIUM 4
Metabolomics a Biochemical Roadmap for Drug Discovery in Alzheimer’s Disease
Chair: Rima Kaddourah Daouk, Duke University Medical Center - Durham (United States)
Discussants: Priyanka Baloni, Institute for Systems Biology, Seattle, WA (United States), Kamil Borkowski, Univ Of California, Davis - Davis (United States)

8.40 a.m ORAL COMMUNICATIONS
Chairs: Rebecca Amariglio, Brigham and Women’s Hospital, Boston, MA (USA), Karim Bennys, Montpellier University Hospital, Montpellier (France)

8.40 a.m OC25 - Divergent longitudinal patterns between participant and study partner report on the Cognitive Function Index in the Harvard Aging Brain Study
Rebecca Amariglio 1, Rachel Buckley 2, Hannah Klinger 2, Kathryn Papp 1, Gad Marshall 1, Catherine Munro 1, Jennifer Gatchel 2, Patrizia Vannini 1, Dorene Rentz 1, Keith Johnson 1, Reisa Sperling 1
1Brigham And Women’s Hospital – Boston, MA (USA), 2Massachusetts General Hospital – Boston, MA (USA)

8.55 a.m OC26 - Functional Connectivity Based Individualized Brain Regions to Measure Tau Propagation: towards application in clinical trials
Diana Svaldi 1, Ixavier Higgins 1, Shcherbinin Sergey 1, Nicolai Franzmeier 2, Michael Ewers 2, Emily Collins 1
1Eli Lilly And Company - Indianapolis (USA), 2University Hospital Munich - Munich (Germany)

9.10 a.m OC27 - Practice Effects in the Letter Fluency Test
Taneisha Arora 1, Daniel Gillen 2, Joshua Grill 2, Michelle Nuño 2
1Google - Mountain View, CA (USA), 2University Of California, Irvine – Irvine, CA (USA), 3University Of Southern California - Los Angeles (USA)

9.25 a.m ORAL COMMUNICATIONS
Chairs: Yan Li, Washington University, St. Louis, MO (USA), Jacques Touchon, University of Montpellier, Montpellier (France)

9.25 a.m LB10 - A Digital Remote Memory Composite to Detect Cognitive Impairment in Memory Clinic Samples in Unsupervised Settings using Mobile Devices
David Berron 1, Ornella Billette 2, Xenia Grande 3, Jeremie Guesten 3, Ina Hempen 4, Annika Spottke 5, Katharina Buerger 6, Robert Pernezcky 6, Christoph Laske 7, Anja Schneider 8, Stefan Teipel 9, Jens Wiltfang 9, Michael Wagner 10, Emrah Duzel 1
1Dzne, Magdeburg - Magdeburg (Germany), 2Neotiv, Magdeburg - Magdeburg (Germany), 3Univ. Magdeburg -Magdeburg (Germany), 4Neotiv. Magdeburg - Magdeburg (Germany), 5Dzne, Bonn - Bonn (Germany), 6Dzne, Munich - Munich (Germany), 7Dzne, Tübingen - Tübingen (Germany), 8Dzne, Rostock - Rostock (Germany), 9Dzne, Göttingen - Göttingen (Germany), 10Dzne, Cologne - Cologne (Germany)

9.40 a.m LB11 - Randomized controlled trial of gamma sensory stimulation treatment demonstrates maintained cognitive and functional abilities and reduced brain atrophy in patients with Alzheimer’s disease
Mihaly Hajos 1, 2, Thomas Meagher 1, 2, Aylin Cimenser 1, Alyssa Boasso 1, Nathan Strozewski 1, Alex Konisky 1, Holly Mrozak 1, Katharine Kolin 1, Martin Williams 1, Evan Hempel 1, Jessie Nicodemus-Johnson 4, Suzanne Hendrix 6, Brent Vaughan 1, Zach Malchano 1
1Cognitionmetrics And Albert Einstein Col Of Medicine - Stamford Ct And Bronx Ny (United States), 2Yale University School of Medicine - New Haven (United States), 3Thompson Autism Center, CHOC Children’s - Orange (United States), 4Pentara Corporation - Millcreek (United States)

9.55 a.m LB12 - The Early Mild Alzheimer’s Cognitive Composite (EMACC): a meaningful primary cognitive endpoint in a phase 2 trial of XPro1595 in Alzheimer’s Disease (AD) with inflammation (ADI)
Judith Jaeger 1, Melanie Buitendyk 2, Christopher J. Barnum 3
1Cognitionmetrics And Albert Einstein Col Of Medicine - Stamford Ct And Bronx Ny (United States), 2Cato-Sms - Wilmington, Nc (United States), 3Immunebio - Boca Raton, Fl (United States)

All sessions to be held in the Grand Ballroom A at Mezzanine Level
**Friday, NOVEMBER 12**

10:10 a.m  
**LB13** - An Examination of Composite Endpoints in 5 Completed or Terminated AD Prevention Trials  
Howard Mackey 1, Angelika Caputo 2, Michael Donohue 3, Nan Hu 1, Jennifer Bogert 4, Jingtao Wu 5, Guoqiao Wang 6  
1Genentech - South San Francisco (United States), 2Novartis Pharma Ag - Basel (Switzerland), 3Alzheimer's Therapeutic Research Institute University Of Southern California - San Diego (United States), 4Janssen Research & Development, Llc - Raritan (United States), 5Takeda - Cambridge (United States), 6Division Of Biostatistics, Washington University - St. Louis (United States)

10:25 a.m  
**LB14** - Positive clinical outcomes of posiphen in two phase2a studies-- Alzheimer disease and Parkinson's disease  
Maria Macccechini 1, Cheng Fang 1, Henrik Zetterberg 2, Michael Chen 3  
1Annovis Bio - Berwyn (United States), 2University Of Gothenburg - göteborg (Sweden), 3Tcm - New Jersey (United States)

10:40 a.m  
Coffee break and poster session (Statler Room) 🌅

11:10 a.m  
**ORAL COMMUNICATIONS**

**OC28** - Concordance Between the Clinical Dementia Rating (CDR) and the Electronic CDR  
Yan Li 1, Taylor Howell 2, Krista Moulder 1, John Morris 1, Michael Weiner 2, Rachel Nosheny 2  
1Washington University In St. Louis - St. Louis (USA), 2University Of California, San Francisco - San Francisco (USA)

11:25 a.m  
**OC29** - Quantification of cognitive impairments in preclinical and early Alzheimer's disease: A proof of concept study to investigate the feasibility, adherence and preliminary clinical validity of remote smartphone-based self-assessments of cognition, function and behavior  
Thanneer Malai Perumal 1, Arnaud Wolfer 1, Florian Lipsmeier 1, Michael Lindemann 1, Foteini Orfaniotou 1, Simone Rey-Riek 1, Irma T Kurniawan 1, Kirsten Taylor 1  
F. Hoffmann La Roche Ltd - Basel (Switzerland)

11:40 a.m  
**OC30** - Integrated Alzheimer's Disease Rating Scale (iADRS): Clinically Meaningful Change Estimates  
Dorene Rentz 1, Alette Wessels 2, Michael Case 2, John Sims 2  
1Harvard Medical School – Boston, MA (USA), 2Eli Lilly and Company – Indianapolis, IN (USA)

11:55 a.m  
**OC31** - A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients with Alzheimer's Disease  
Kee-Hyung Park 1, Won Yang Dong 2, Mee Young Park 1, Seong Hye Choi 4, Hyun Jeong Han 4, Hee Jin Kim 3, Kyung Won Park 6, Yuan-Han Yang 7, Suraya Yusoff 8, Gurudev M. Kewalram 9, Seol-Heui Han 10  
1Gachon University Gil Medical Center - Incheon (Korea, Republic of), 2The Catholic University Of Korea, Seoul St. Mary's Hospital - Seoul (Korea, Republic of), 3Yeungnam University Hospital - Daegu (Korea, Republic of), 4Inha University Medical Center - Incheon (Korea, Republic of), 5Yonsei University College of Medicine - Seoul (Korea, Republic of), 6Yonsei University Seoul Hospital - Seoul (Korea, Republic of), 7Ewha Womans University Hospital - Seoul (Korea, Republic of), 8University of Malaya - Kuala Lumpur (Malaysia), 9Korea University - Seoul (Korea, Republic of), 10Konkuk University Medical Center - Seoul (Korea, Republic of)

12:10 p.m  
Lunch* (ABC Room) and Poster Session (Statler Room) 🌇

*for attendees who pre-purchased lunch

1:10 p.m  
**SYMPOSIUM 5**  
Diversity in Alzheimer's Disease Clinical Trials  
Chair: Phyllis Barkman Ferrell, Eli Lilly & Company, Indianapolis, IN (USA), Holly Massett, National Institute on Aging, U.S. National Institutes of Health, Bethesda, MD, USA

**Presentation 1:** BRAIN INFO LIVESM: A Free Virtual Outreach Series Reaching Underrepresented US Populations, Bright Focus Foundation  
Nancy Lynn, BrightFocus Foundation, Los Angeles, California, USA

**Presentation 2:** Harnessing Community Data to Drive Brain Health Equity – the National Alzheimer’s Disease Index  
Jason Resendez, Executive Director, UsAgainstAlzheimer's Center for Brain Health Equity; Washington, DC

**Presentation 3:** Building an inclusive science that addresses inclusive diverse trials – the NEWIDEAS Study, Alzheimer's Association Consortia  
Peggye Dilworth-Anderson, PhD, Gillings School of Global Public Health UNC; Chapel Hill, NC, USA
Friday, NOVEMBER 12

1.50 p.m ORAL COMMUNICATIONS

Chairs: Roberta Diaz Brinton, University of Arizona Health Sciences, Tucson, AZ (USA), Jacques Touchon, University of Montpellier, Montpellier (France)

1.50 p.m OC32 - Update on the Phase 2 Study of AL001 in Frontotemporal Dementia Patients Carrying a Granulin Mutation

Robert Paul 1, Felix Yeh 1, Mike Ward 1, Sam Jackson 1, Herve Rhinn 1, Julie Huang 1, Jenna Pappalardo 1, Yijie Liao 1, Hua Long 1
Alector, Inc. - South San Francisco (USA)

2.05 p.m OC33 - Centiloid scales may represent a robust clinical outcome for anti-Ab therapeutic trials across diverse populations/locations

Samantha C Burnham 1, Timothy Cox 2, Pierrick Bourgeat 3, Vincent Doré 3, Duygu Tosun 4, Manu Goyal 3, Rosita Shishegar 5, Parnesh Raniga 5, Simon Laws 4, Tenielle Porter 4, Jurgen Fripp 2, Tammie Benzinger 1, Walter Kukull 8, Christopher C Rowe 8, John C Morris 7, Mike Weiner 4, Colin L Masters 10, Victor LiVillemane 11
1The Australian E-Health Research Centre, CSIRO Health & Biosecurity - Parkville (Australia), 2The Australian E-Health Research Centre, CSIRO Health & Biosecurity - Canberra (Australia), 3The Australian E-Health Research Centre, CSIRO Health & Biosecurity - Herston (Australia), 4Department Of Radiology And Biomedical Imaging, University Of California-San Francisco - San Francisco (USA), 5Neuroimaging Laboratories, Mallinckrodt Institute Of Radiology, Washington University School Of Medicine - St. Louis (USA), 6Department Of Radiology, University Of Washington - Seattle (USA), 7Department Of Molecular Imaging & Therapy, Austin Health - Heidelberg (Australia), 8Centre For Precision Health, School Of Medical And Health Sciences, Edith Cowan University - Joondalup (Australia), 9Knight Alzheimer Disease Research Center, Washington University School Of Medicine - St. Louis (USA), 10Department Of Epidemiology, University Of Washington - Seattle (USA), 11Department Of Psychiatry, University Of Pittsburgh School Of Medicine - Pittsburgh (USA)

2.20 p.m OC34 - A machine learning tool to enrich Alzheimer’s disease clinical trials in presymptomatic cohorts

Angela Tam 1, César Laurent 1, Christian Dansereau 1
Perceiv Research Inc - Montreal (Canada)

2.35 p.m OC35 - The Internet-based conversational engagement clinical trial (I-CONECT) in socially isolated adults 75+ years old: Randomized controlled trial protocol and COVID-19 related study modifications

Kexin Yu1, Lisa C. Silbert 2, Katherine Wild2, Jeffrey A. Kaye2, Elena L. Alfaro3, Jacob Lindsey 4, 5, Colón Scavone6, Mattie Mcdonald2, 5, Hiroko H. Dodge2
1University Of Southern California - Los Angeles (USA), 2Oregon Health & Science University - Portland (USA), 3University Of Wisconsin-Madison - Madison (USA), 4Oregon State University – Corvallis, OR (USA), 5Syneos Health - Portland, OR (USA)

2.50 p.m OC36 - Development of a novel digital speech composite measure for Frontotemporal Dementia

Jessica Robin 1, Mengdan Xu 1, Liam Kaufman 1, William Simpson 1, Michael Ward 1, Robert Paul 1
Winterlight Labs - Toronto (Canada), Alector, Inc. - South San Francisco (USA)

3.05 p.m OC37 - Longitudinal safety, clinical, and beta amyloid PET outcomes of a multi-center clinical trial of focused ultrasound blood brain barrier (BBB) opening of the hippocampus, frontal and parietal lobes in early Alzheimer’s disease

Ali Rezaei 1, Manish Ranjan 1, Mark Haut 1, Jeffrey Carpenter 1, Umer Najib 1, Rashi Mehta 1, Pierre-Francois D'haese 1, J. Levi Chazen 2, Zion Zibby 1, Daniel Claassen 4, Peter Konrad 1, Sally Hodder 5, Michael Kaplitt 2
1WVU Rockefeller Neuroscience Institute - Morgantown (USA), 2Weill Cornell Medicine - New York (USA), 3Sheba Medical Center - Ramat Gan (Israel), 4Vanderbilt University - Nashville (USA), 5West Virginia Clinical and Translational Institute - Morgantown (USA)

3.20 p.m Statistics workshop: re-thinking trial outcomes

Statistical Properties of iADRS Like Composites in Alzheimer’s Disease

Paul Aisen, MD, ATRI at USC, San Diego, CA (USA), Hong Liu Seifert, Eli Lilly & Company, Indianapolis, IN (USA), Suzanne Hendrix, Pentara Corporation, Millcreek, UT (USA)
## Onsite Poster Presentations

- **THEME**
  - Animal model and clinical trial
  
  - Behavioral disorders and clinical trials
  
  - Clinical trials: cognitive and functional endpoints
  
  - Clinical trials: imaging
  
  - Clinical trials: biomarkers including plasma
  
  - Clinical trials: methodology
  
  - Clinical trials: results
  
  - Cognitive assessment and clinical trials
  
  - Epidemiology and clinical trials
  
  - Digital health/E-trials
  
  - Health economics and clinical trials
  
  - New therapies and clinical trials
  
  - Proof of concept/Translational research for Alzheimer Drug Development interventions

---

Poster presented onsite in Boston

All posters are available in the Statler Room with specific “Meet the Presenters” sessions during coffee breaks and lunches.

All these posters are also available on the digital platform.
THEME
Animal model and clinical trial

P1  Treatment of Alzheimer’s disease by a proteosome-based adjuvant (Protollin) that modulates both peripheral monocytes and disease-associated microglia
Panayota Kolypetri  
Brigham Women’s Hospital – Boston, MA (USA)

THEME
Behavioral disorders and clinical trials

P2  Mapping Items of the Cohen-Mansfield Agitation Inventory onto International Psychogeriatric Association's agitation definition: data from the brexpiprazole phase 3 program for the treatment of agitation in Alzheimer’s dementia
Ross A. Baker 1, Eva Kohegyi 1, Ismail Zahinooor 2  
1Otsuka – Princeton, NJ (USA), 2University of Calgary - Calgary (Canada)

P3  Veterans in AD Prevention Clinical Trials: An evaluation of the association of TBI on memory and global cognition
Carol Van Hulle 1, Madison Rundell 1, Karen Lazar 1, Elena Beckman 1, Noele Brandon 1, Carey Gleason 1, Sterling Johnson 1, Sanjay Asthana 1, Cynthia Carlsson 1  
University of Wisconsin-Madison – Madison, WI (USA)

P4  Low dose lithium treatment of behavioral complications in Alzheimer’s disease: Lit-AD randomized clinical trial
Davangere Devanand 1, Elizabeth Crocco 1, Brent Forester 1, Mustafa Husain 1, Seonjoo Lee 1  
Columbia University Irving Medical Center - New York (USA)

LRP2  Pimavanserin treatment of hallucinations and delusions in patients with Parkinson's disease dementia: post hoc analysis of the HARMONY trial
Daniel Weintraub 1, Alberto Esparza 1, Vibhash Sharma 1, Pierre Tariot 1, Victor Abler 2, Sanjeev Pathak 2, Srdjan Stankovic 1  
1Departments Of Psychiatry And Neurology, Perelman School Of Medicine At The University Of Pennsylvania - Philadelphia (United States), 2Gardner Family Center For Parkinson’s Disease And Movement Disorders, Department Of Neurology, University Of Cincinnati - Cincinnati (United States), 3Department Of Neurology, University Of Kansas Medical Center - Kansas City (United States), 4Banner Alzheimer’s Institute And University Of Arizona College Of Medicine - Phoenix (United States), 5Acadia Pharmaceuticals Inc. - San Diego (United States)

THEME
Clinical trials: cognitive and functional endpoints

P7  iADRS: demonstration of clinical meaningfulness by association of health-related quality of life outcome assessments
Julie Chandler 1, Mark Belger 1, Alette Wessels 1, Joe Johnston 1, Dorene Rentz 2, James Murray 1, John Sims 1  
1Eli Lilly And Company - Indianapolis (USA), 2Department Of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (USA), 3Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School - Boston (USA)

P8  Repeated administration of autologous adipose tissue-derived stem cells improved cognitive function in Alzheimer's disease
Kazuhi Shigematsu 1, Kazunari Ishii 1, Naoyuki Komori 3, Kenichi Tahara 3, Hisakazu Yamagishi 3  
1Minami Kyoto Hospital - Kyoto (Japan), 2Nagitsuji Hospital - Kyoto (Japan), 3Department Of Radiology, Kindai University Faculty Of Medicine - Osaka (Japan), 4Takara Bio Inc - Kusatsu (Japan), 5Kyoto Prefectural University Of Medicine - Kyoto (Japan)

P9  The Influence of Level of Education on Instrumental Activities of Daily Living in Patients with Alzheimer’s Disease
Carina Wattmo  
Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University - Malmö (Sweden)

P10  Low-dose Whole Brain Radiation Therapy for Early Alzheimer’s Dementia: Early Results from a Phase IIa Trial
Leland Rogers 1, Sarah Lageman 1, John Karis 1, Minesh Mehta 1, James Fontanesi 2  
1GammaWest Cancer Services - Salt Lake City, UT (USA), 2Barrow Neurological Institute - Phoenix, AZ (USA), 3Miami Cancer Institute - Miami, FL (USA), 4William Beaumont Hospital - Auburn Hills, MI (USA)

P11  AMBAR Treatment Effect Size Compared to Monoclonal Antibody Study Effect Sizes
Samuel Dickson 1, Suzanne Hendrix 1, Jessie Nicodemus Johnson 1, Miquel Barcelo 2, Merce Boada 3, Oscar Lopez 1, Laura Nunez 2, Carlota Grifols 2, Antoni Paez 2  
1Pentara Corporation - Mill Creek (USA), 2Grifols - Barcelona (Spain), 3Universitat Internacionnal De Catalunya - Barcelona (Spain), 4Instituto de Salud Car
LP1

Validation of the Learning Ratio derived from the RAVLT in Early-Onset Alzheimer’s Disease from the LEADS study
Dustin Hammers 1, Taylor Diedrich 1, Sara Nemes 1, Ani Eloyan 2, Joel Kramer 1, Paul Aisen 3, Maria Carillo 1, Bradford Dickerson 4, Gil Rabinovici 1, Liana Apostolova 1, Leads Leads Consortium 1
1Indiana University - Indianapolis (United States); 2Brown University - Providence (United States); 3University Of California San Francisco - San Francisco (United States); 4University Of Southern California - Los Angeles (United States); 5Alzheimer’s Association - Chicago (United States); 6Mass General Brigham Harvard Boston (United States) - Boston (United States)

LP2

Sensitivity of the Preclinical Alzheimer’s Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer Disease – Atabecestat Phase 2b/3 EARLY Clinical Trial
Kate Papp 1, Hany Rofael 2, Amy Veroff 3, Mike Donohue 4, Shunan Wang 1, Christopher Randolph 1, Ellen Grober 4, H. Robert Brashear 7, Gerald Novak 8, Karin Ernstrom 4, Rema Raman 4, Paul Aisen 4, Reisa Sperling 1, Gary Romano 6, David Henley 8
1Harvard Medical School - Boston (United States); 2Janssen Research And Development - Titusville (United States); 3Consultant - Bethesda (United States); 4University Of Southern California - San Diego (United States); 5Medavante - Hamilton (United States); 6Albert Einstein College Of Medicine - Bronx (United States); 7University Of Virginia - Charlottesville (United States); 8Janssen - Titusville (United States); 9Indiana University School Of Medicine - Indianapolis (United States)

THEME
Clinical trials: imaging

P12

An automated MRI face-removal pipeline to anonymize patient scans for clinical trials
Łukasz Kidzinski 1, Thomas Cajgfinger 1, Kevin Thomas 1, Luc Bracoud 1, Po-Han Chen 1, Shao-Yu Lin 1, Joomin Oh 1, Chun-Chiang Shen 1, Chris Conklin 1, Joël Schaerer 1, David Scott 1, Joyce Suh 1
1Bioclinica - San Mateo (USA); 2Bioclinica - Lyon (France), 3Bioclinica - Taiwan, Republic of China, 4Bioclinica - Princeton (USA)

P13

Free water imaging as a tool for understanding Alzheimer's Disease
Richard Parker 1, Richard Joules 1, Robin Wolz 1
1ixica Plc - London (United Kingdom)

P14

Impact of Age and APOE4 carrier status in subjects at-risk for AD on microhemorrhages, white matter lesions and brain volume: Preliminary analyses
Luc Bracoud 1, Marie-Emmanuelle Rivière 1, David Scott 1, Chris Conklin 4, Angelika Caputo 2, Joyce Suh 1, Ana Graf 2
1Bioclinica - Lyon (France), 2Novartis Pharma Ag - Basel (Switzerland), 3Bioclinica - San Mateo (USA), 4Bioclinica - Princeton (USA)

P15

Towards computer-assisted detection of ARIA-E occurrence
Thomas Cajgfinger 1, Luc Bracoud 1, Derk Purcell 2, Joël Schaerer 1, Marco Lyons 3, Zsofia Bullain 3, Jakub Wojtowicz 4, Chris Conklin 1, David Scott 1, Joyce Suh 1, Gregory Klein 3
1Bioclinica - Lyon (France), 2California Pacific Medical Center - San Francisco (USA), 3Roche/genentech Product Development, Neuroscience - Basel (Switzerland), 4Roche Pharma Research and Early Development - Basel (Switzerland), 5Bioclinica - Princeton (USA), 6Bioclinica - San Mateo (USA)

P16

Allopregnanolone as a Regenerative Therapeutic for Alzheimer’s Disease: Phase 2 proof-of-concept clinical trial using hippocampal volume as a surrogate endpoint
Gerson Hernandez 1, Lon Schneider 2, Dawn Matthews 3, Kathleen Rodgers 1, Claudia Lopez 1, Yvette Wang 1, Adam Raikes 2, Gary Cutter 4, Roberta Brinton 1
1Center For Innovation In Brain Science, University Of Arizona - Tucson (USA); 2Keck School Of Medicine Of USC - Los Angeles (USA); 3Adm Diagnostics - Chicago (USA), 4Uab School Of Public Health - Birmingham (USA)

P17

Safety, Tolerability and Cerebral Blood Flow After Single Doses of the β2-agonist, Clenbuterol, in Patients with Mild Cognitive Impairment or Parkinson’s Disease
Thomas Lodeweyckx 1, Jan De Hoorn 1, Koen Van Laere 2, Michel Koole 1, Wim Vandenberghe 3, Courtney Bishop 4, Eugenii Rabiner 5, Renee Martin 5, Anthony Ford 1, Gabriel Vargas 1
1Department Of Pharmaceutical And Pharmacological Sciences, Ku Leuven - Leuven (Belgium), 2Division Of Nuclear Medicine, University Hospital Leuven And Nuclear Medicine And Molecular Imaging - Durham (USA), 3Department Of Neurology, University Hospital Leuven - Leuven (Belgium), 4Invicro, A Konica Minolta Company - London (United Kingdom), 5Curosen Therapeutics, Inc - San Carlos, California (USA)

P19

Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals
Lyduine Collij 1, Sophie Mastenbroek 1, Gemma Salvadó 2, Alle Meie Wink 1, Pieter Jelle Visser 1, Frederik Barkhof 1, Bart Berckel Van 1, Isadora Lopes Alves 1
1Amsterdam Umc - Amsterdam (Netherlands), 2BarcelonaBeta Brain Research Center - Barcelona (Spain)

LP3

Novel white matter imaging measures of neuroinflammation, axonal density and demyelination as potential biomarkers for trials in the AD spectrum: validation in the largescale longitudinal multicenter ADNI studies
Maggie Roy 1, Matthieu Dumont 1, Jean-Christophe Houde 1, Raymond Tesi 1, Christopher Barnum 2, Maxime Descoteaux 1, Alzheimer’s Disease Neuroimaging Initiative Alzheimer’s Disease Neuroimaging Initiative 3
1Imeka Solutions Inc - Sherbrooke (Canada), 2Innyme Bio, Inc - San Diego (United States), 3Alzheimer’s Disease Neuroimaging Initiative - San Diego (United States)

LP4

MRI measures of white matter pathology in AD clinical trials – case study from the XPro595 phase 1 trial in Alzheimer’s patients with neuroinflammation
Maxime Descoteaux 1, 2, Maggie Roy 1, Matthieu Dumont 1, Jean-Christophe Houde 1, Parris Pope 3, R J Tesi 1, C J Barnam 3
1Imeka Solutions Inc - Sherbrooke (Canada), 2Université de Sherbrooke - Sherbrooke (Canada), 3Innyme Bio Inc - San Diego (United States)
POSTERS presented onsite

LP5 Anatomical and functional connectivity of the Nucleus Basalis in Alzheimer’s Disease
Sergio Becerra 1, 2, Sheldon Jordan 1, 2, Taylor Kuhn 1, 2, Kennedy Mahdavi 1, Jon Haroon 1, Margaret Zielinski 1
1Synaptec Network - Santa Monica, Ca (United States), 2UCLA - Los Angeles, Ca (United States)

THEME Clinical trials: biomarkers including plasma

P20 Microglia biomarkers in Alzheimer’s disease
Peng Fei Zhang
Qingdao University - Qingdao (China)

P22 Alzheimer’s disease Patients have Impaired CSF Egress due to Atrophy of the Cribriform Plate
Douglas Ethell 1, 2, Ricardo Zaragoza 1, Javed Siddiqi 3, Daniel Miuli 4
1Leucadia Therapeutics Inc - Riverside (USA), 2La Jolla Immunology Institute - San Diego (USA), 3Desert Regional Med Ctr - Palm Springs (USA), 4Arrowhead Regional Med Ctr - Colton (USA)

P23 Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer’s disease
Shi-Dong Chen 1, Qiang Dong 1, Jin-Tai Yu 1
Department Of Neurology And Institute Of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University - Shanghai (China)

P24 Can EEG biomarkers differentiate Alzheimer’s disease dementia vs. non-AD dementia?
Pieter Van Mierlo 1, 2
1Ghent University - Ghent (Belgium), 2Epilog Nv - Ghent (Belgium)

P26 Characterization of Alzheimer’s tau biomarker discordance using plasma, CSF and PET
Guo Yu
Department Of Neurology And Institute Of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China - Shanghai (China)

LP6 Extracellular vesicle biomarkers of insulin signaling associate with age-related change in CSF biomarkers of Alzheimer’s disease in adults without dementia
Gilda Ennis 1, Erden Eren 2, Yue Ma 1, Connine Engelman 1, Rozalyn Anderson 1, Ivonne Suridjan 3, Gwen Kollmorgen 4, Cynthia Carlsson 1, Sanjay Asthana 1, Sterling Johnson 1, Henrik Zetterberg 1, Kaj Blennow 5, Barbara Bendlin 1, Dimitrios Kapogiannis 2
1University Of Wisconsin-Madison - Madison (United States), 2National Institute On Aging - Baltimore (United States), 3Roche Diagnostics International Ltd - Rotkreuz (Switzerland), 4Roche Diagnostics GmbH - Penzberg (Germany), 5University Of Gothenberg - Gothenburg (Sweden)

LP8 Cerebrospinal Fluid Biomarkers in Early Alzheimer’s Disease Subjects with APOE4/4 and APOE3/4 Genotypes: Baseline Data from Phase 2 Biomarker Study with Oral Anti-Amyloid Agent ALZ-801
John Hey 1, Susan Abushakra 1, Aidan Power 1, Sterre Rutgers 2, Katerina Sheardova 3, Paul Dautzenberg 4, Niels Prins 2, Ladislav Pazdera 4, Earvin Liang 1, Kaj Blennow 5, Philip Scheltens 2, Jakub Hort 1, Martin Tolar 2
1Alzheon Inc. - Framingham (United States), 2Bioclinica - Amsterdam (Netherlands), 3St. Anne University Hospital - Brno (Czech Republic), 4Brain Research Center - Den Bosch (Netherlands), 5Vestra Research Clinics - Rychnov And Knézou (Czech Republic), 6Gothenburg University - Molndal (Sweden), 7Amsterdam University Medical Centers, Alzheimers Center Amsterdam (Netherlands), 8Amsterdam University Cognitive Center, Motol Hospital - Prague (Czech Republic)

LP9 Brain Hippocampal Volume and Cortical Thickness in Early Alzheimer’s Disease Subjects with APOE4/4 and APOE3/4 Genotypes: Baseline Data from Phase 2 Biomarker Study with the Oral Anti-Amyloid Agent ALZ-801
Susan Abushakra 1, John Hey 1, Luc Bracoud 1, Aidan Power 2, Joyce Suhy 1, Jakub Hort 1, Sheardova Katerina 2, Pazdera Ladislav 4, Rutgers Sterre 7, Scheltens Philip 2, Tolar Martin 2
1Alzheon Inc. - Framingham (United States), 2Bioclinica - Leon (France), 3Bioclinica - San Mateo (United States), 4Charles University - Prague (Czech Republic), 5St. Anne University Hospital - Brno (Czech Republic), 6Vestra Research Clinics - Rychnov And Knézou (Czech Republic), 7Brain Research Center - Amsterdam (Netherlands), 8Amsterdam University Alzheimer Center - Amsterdam (Netherlands)

THEME Clinical trials: methodology

P27 Placebo-effect size in symptomatic Alzheimer’s Disease Clinical Trials
Nadine Mader 1, Peter Schueler 2
1Univ Duisburg Essen - Bad Vilbel (Germany), 2Icon - Langen (Germany)

P28 Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress and Cognition in Mild Cognitive Impairment and Mild Alzheimer’s Disease
Isabella Santangelo 1, Morgan Green 1, Regan Patrick 1, David Harper 1, Tao Song 1, Chenyanwen Zhu 1, Boyu Ren 1, Brent Forester 1, Fei Du 1
Mclean Hospital - Belmont (USA)
POSTERS presented onsite

P30  Caring for Behavioral Symptoms of Dementia (CBD): A New Investigation into Cannabidiol for the Treatment of Anxiety and Agitation in Alzheimer’s Dementia
Kaitlin Mcmanus 1, Rosemary Smith 1, Regan Patrick 1, David Harper 1, Staci Gruber 1, Brent Forester 1
Mclean Hospital - Boston (USA)

P31  ECT-AD Trial: Challenges to Startup & Recruitment
Maria Lapid 1, Brent Forester 2, George Petrides 1, Adriana Hermida 4, Louis Nykamp 3, Martina Mueller 3, Regan Patrick 2
1Mayo Clinic - Rochester, Mn (USA), 2Mclean Hospital - Belmont, Ma (USA), 3Northwell Health/zucker Hillside Hospital - Glen Oaks, Ny (USA), 4Emory University Healthcare - Atlanta, Ga (USA), 5Pine Rest Christian Mental Health Services - Grand Rapids, Mi (USA), 6Medical University Of South Carolina - Charleston, Sc (USA)

P32  The Impact of MMSE Administration Errors on MMSE Change One Year After Randomization: A Preliminary Analysis of Pooled Data
David Miller 1, Xingmei Wang 1, Alan Kott 1
1Signant Health - Blue Bell, PA (USA)

P33  The AHeED Study: Ambroxol in New and Early Dementia with Lewy Bodies
Arvid Rongve
Haugesund (Norway)

P34  Age affects clinical outcome in Alzheimer’s disease trials
Steven Tarum 1, Lisa Fosdick 2, Kristin Drake 1, Paul Rosenberg 3, Anna Burke 1, David Wolk 4, Kelly Foote 5, Wael Asaad 6, Marwan Sabbagh 9, Gwenn Smith 10, Andres Lozano 11, Constantine Lyketsos 12
1Neurol Medicine, University of Miami - Miami (USA), 2Neurology, University of Miami - Miami (USA), 3Neurology, University of Miami - Miami (USA), 4Neurology, University of Miami - Miami (USA), 5Neurology, University of Miami - Miami (USA), 6Neurology, University of Miami - Miami (USA), 7Department of Neurology, University of Miami - Miami (USA), 8Department of Neurology, University of Miami - Miami (USA), 9Department of Neurology, University of Miami - Miami (USA), 10Department of Neurology, University of Miami - Miami (USA), 11Psychiatry, University of Miami - Miami (USA), 12Psychiatry, University of Miami - Miami (USA)

P35  Effects of inclusion/exclusion criteria on ethnocultural and socioeconomic composition of participants in an Alzheimer’s disease clinical trial: Analysis of Health and Retirement Study (HRS) data
Miriam T. Ashford 1, Mohammed U. Kabeto 2, Caroline R. Wixom 3, 4, 5, Rachel L. Nosheny 6, Michael W. Weiner 7, David R. Weir 8
1Northern California Institute For Research And Education (ncire), Department Of Veterans Affairs Medical Center - San Francisco (USA), 2Department Of Internal Medicine, University Of Michigan - Ann Arbor (USA), 3Department Of Internal Medicine, University Of Michigan - Ann Arbor (USA), 4Department Of Internal Medicine, University Of Michigan - Ann Arbor (USA), 5Department Of Internal Medicine, University Of Michigan - Ann Arbor (USA), 6Department Of Radiology And Biomedical Imaging, University Of California San Francisco - San Francisco (USA), 7Institute For Social Research, University Of Michigan - Ann Arbor (USA), 8Institute For Healthcare Policy and Innovation, University Of Michigan - Ann Arbor (USA)

P36  A machine learning tool to enrich early Alzheimer’s disease clinical trial cohorts
Angela Tam 1, César Laurent 1, Christian Dansereau 1
Perceiv Research Inc - Montreal (Canada)

P37  Enhancing the Enrollment of Underrepresented Minority Populations in Clinical Trials Through the Global Alzheimer’s Platform Foundation’s® (GAP’s) Diversity and Inclusion Program
Tamiko Rodgers 1, Leigh Zisko 1, John Dwyer 1, Judith Jeter 1, Cyndy Cordell 1
Global Alzheimer’s Platform Foundation – Washington, Dc (USA)

P38  Comprehensive evaluations of some mixed models for clinical trial analysis in Alzheimer disease
Guoqiao Wang
Washington University In St Louis - St Louis, Mi (USA)

P39  Predicting Amyloid Positivity Using Machine Learning-Based Risk Scores
Kellen Petersen 1, Ali Ezzati 1, Richard Lipton 1, Ellen Grober 1
Albert Einstein College of Medicine – Bronx, Ny (USA)

P40  Determining the Probability of Success in a Clinical Development Program for a Disease Modifying AD Treatment
Suzanne Hendrix 1, Newman Knowlton 1, Jessie Nicodemus Johnson 1, Sean Hennessey 1, Samuel Dickson 1
Pentara Corporation - Salt Lake City (USA)

LP10  Preclinical AD Research and the Electronic Medical Record (EMR): Balancing Confidentiality and Participant Safety
Seth Gale 1, Judith Heidebrink 2, Jonathan Griff-Radford 3, Joshua Grill 4, Gregory Jicha 5, Jason Karlawish 6, William Menard 7, Milap Nowrangi 8, Susi Sami 1, Shirley Sirivong 4, Sarah Walter 10
1Bramhall And Women’s Hospital - Boston (United States), 2University Of Michigan - Ann Arbor (United States), 3Mayo Clinic - Rochester (United States), 4University Of California - Irvine (United States), 5University Of Kentucky - Lexington (United States), 6University Of Pennsylvania - Philadelphia (United States), 7Butler Hospital, Memory And Aging Center - Providence (United States), 8Johns Hopkins University - Baltimore (United States), 9Case Western Reserve University - Cleveland (United States), 10Alzheimer’s Therapeutic Research Institute, University Of Southern California - San Diego (United States)
**Planning for Success: a Three-step process to Define Phase II Trial Size and Duration Using a Patient Enrichment Strategy using Phase I Data and Public Databases**

Cj Barnum 1,2, Descoteaux Maxime 3, Roy Maggie 4, Dumont Matthieu 4, Jean-Christophe Houde 4, Melanie Buitendyk 3, Judith Jaeger 4, Rj Tesi 1

1 Immune Bio Inc - Boca Raton (United States), 2 Imeka Solutions Inc - Sherbrooke (Canada), 3 Universite De Sherbrooke - Sherbrooke (Canada), 4 Imeka Solutions Inc - Sherbrooke (Canada), 5 Cato-Sms - Wilmington (United States), 6 Cognition Metrics Llc - Springfield (United States)

**Preferences for Disclosure of Biomarker and Genetic Results in Alzheimer’s Research: Feedback from a Participant Advisory Board**

Sarah Walter 1, Adam Boxer 2, Joshua D. Grill 3, Jason Karlawish 4, Shaffer Elizabeth 1, Jaimie Ziolkowski 5, Paul Aisen 1

1 alzheimer’s Therapeutic Research Institute, University Of Southern California - San Diego (United States), 2 university Of California, San Francisco - San Francisco (United States), 3 university Of California, Irvine - Irvine (United States), 4 university Of Pennsylvania, Perlman Medical School - Philadelphia (United States), 5 University Of Michigan - Detroit (United States)

**CPAD: Accelerating Alzheimer’s disease drug development through pre-competitive data sharing and generation of data-driven quantitative drug development tools**

Sudhir Sivakumaran 1, Jackson Burton 1, Yashmin Karten 1, Zihan Cui 1, Bob Stafford 1, Corissa Lau 1, Eileen Priest 1, Hazel White 1, Michael Irizarry 2, Klaus Romero 2

1 Critical Path Institute - Tucson (USA), 2Eisai Inc. - Woodcliff Lake (USA)

**Interim Results of an Open-label Study of Simufilam in Mild-to-Moderate Alzheimer’s Disease**

Lindsay Burns 1, Tamara Doehner 1, John Puente 1, Brian Beck 1, Yaneicy Gonzalez Rojas 2, Evelyn Lopez-Bignonni 3, Boris Nikolov 3, Ben Murray 1, Antonio Hernandez 1, Carrie Crowley 1, Nadav Friedmann 1

1 Cassava Sciences - Austin (United States), 2Cognitive Clinical Trials - Omaha (United States), 3Cognitive Clinical Trials - Phoenix (United States), 4Optimus U - Miami (United States), 5Imic Research - Palmetto Bay (United States)

**A Phase 1 Study of AL003 in Healthy Volunteers and Participants with Alzheimer’s disease**

Mike Ward 1, Felix Yeh 1, Hua Long 1, Tina Schwabe 1, Herve Rhinn 1, Ilaria Tassi 1, Daniel Maslyar 1, Madeline Spencer 1, Candace Hagey 1, Glenn Morrison 1, Robert Paul 1

Alector, Inc. - South San Francisco (USA)

**A First-in-human Study of the anti-Sortilin antibody AL101**

Mike Ward 1, Daniel Maslyar 1, Felix Yeh 1, Hua Long 1, Michael Kurnellas 1, Emmanuel Ang 1, Amber Silva 1, Robert Paul 1

Alector Inc. - South San Francisco (USA)

**Positive clinical outcomes of posiphen in two phase2a studies-- Alzheimer’ disease and Parkinson’s disease**

Maria Maccecchini 1, Cheng Fang 1, Henrik Zetterberg 2, Michael Chen 3

1 Annovis Bio - Berwyn (United States), 2University Of Gothenburg - göteborg (Sweden), 3Tcm - New Jersey (United States)

**Impact of Alzheimer’s disease (AD) related co-pathology on treatment effects of the oral p38α kinase inhibitor neflamapimod in mild-to-moderate dementia with Lewy bodies (DLB)**

John Alam 1, Stephen Gomperts 1, Afina Lemstra 1, Inge Verberk 1, Sherif Bayoumi 1, Hui-May Chu 1, Amanda Gardner 1, Kelly Blackburn 1, Niels Prins 2, Charlotte Feunisen 4

1 Eip Pharma - Boston (United States), 2Massachusetts Alzheimer’s Disease Research Center - Boston (United States), 3Massachusetts General Hospital - Boston (United States), 4Amsterdam Umc - Amsterdam (Netherlands), 5Brain Research Center - Amsterdam (Netherlands), 6Amnoxis Corporation - Natick (United States)

**Safety and Biological Activity of a Fixed-Dose Conformulation of Sodium Phenylbutyrate and Taurursodiol (PB/TURSO) for the Treatment of Alzheimer’s Disease: Results From the Phase 2a PEGASUS Study**

Steven E. Arnold 1, Suzanne Hendrix 2, Jessie Nicodemus-Johnson 3, Newman Knowlton 3, Alison J. Mcmanus 1, Monica Crane 1, Sanjeev N. Vaishnavi 4, Jeffrey M. Burns 1, Zoe Arvanitakis 5, Judith Neugroschl 1, Victoria J. Williams 3, Rudolph E. Tanzi 5, Patrick D. Yeramian 6, Kent Leslie 10

1 Department Of Neurology, Massachusetts General Hospital, Boston, Ma - Boston (United States), 2Pentara Corporation, Millcreek, Ut - Millcreek (United States), 3Genesis Neuroscience Clinic, Knoxville, Tn - Knoxville (United States), 4Department Of Neurology, Perelman School Of Medicine At The University Of Pennsylvania, Philadelphia, Pa - Philadelphia (United States), 5Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, Il - Chicago (United States), 6Department Of Psychiatry, Icahn School Of Medicine At Mount Sinai, New York, Ny - New York (United States), 7Department Of Medicine, University Of Wisconsin-Madison, School Of Medicine And Public Health, Madison, Wi - Madison (United States), 8Amylyx Pharmaceuticals, Inc., Cambridge, Ma - Cambridge (United States)
POSTERS presented onsite

LP17  Mapping the Cohen-Mansfield Agitation Inventory to the Clinical Global of Severity of Agitation: data from the brexpiprazole phase 3 program for the treatment of agitation in Alzheimer’s dementia
Anne De Jong-Laird 1, Pedro Such 2, Dalei Chen 3, Ross Baker 3
1Otsuka - The Hague (Netherlands), 2Lundbeck - Copenhagen (Denmark), 3Otsuka - Princeton (United States)

LP18  Final Data From a Phase 1 Single-Ascending-Dose Trial of PNT001, A Monoclonal Antibody Uniquely Recognizing cis-pT231 Tau for Treatment of Tauopathies
Wendy Luca 1, Kelly Foster 1, Kim Mc Clure 1, Martin Jefson 1, Michael Ahlijanian 1, Larry Altstiel 1
Pintleto Therapeutics - Newton Centre (United States)

THEME  Cognitive assessment and clinical trials

P48  Cultural Influence on CDR Scores: Comparison across Seven Geo-Cultural Groups
Sayaka Machizawa 1, Todd Feaster 1, Jessica Stenclik 1, Zinan Chen 1, Danielle Digregorio 1
Signant Health - Blue Bell (USA)

P49  Geo-Cultural Influences on MMSE Total Score in Alzheimer’s Disease Trials
Jessica Stenclik 1, Sayaka Machizawa 1, Zinan Chen 1, Todd Feaster 1
Signant Health - Blue Bell (USA)

P50  Different methods of identifying rapid cognitive decliners for Alzheimer’s Disease
Haiyang Zhang 1, Jason Goode 1, Michael Donahue 3, Ali Torkamani 3, Jared Cara 1, Julie Collens 1
1Vivid Genomics - San Diego (USA), 2University Of Southern California - Los Angeles (USA), 3Scripps Research Institute - San Diego (USA)

P53  Detection of Pre-clinical Alzheimer’s Disease with Simultaneous Modeling of Underlying Cognitive Processes in Recall and Recognition Tests
Jason Bock 1, Michael Lee 2, William Shankle 1-2-3, Junko Hara 1-2-3, Dennis Fortier 1, Tushar Mangrola 1
1Embic - Newport Beach (USA), 2Dept. Of Cognitive Sciences, University Of California At Irvine - Irvine (USA), 3Pickup Family Neuroscience Institute, Hoag Memorial Hospital - Newport Beach (USA)

P54  An exploration of minimal clinically important differences for cognitive outcomes in preclinical and prodromal stages – implications for clinical AD trials
Emma Borland 1, Chris Edgar 2, Erik Stomrud 1, Nicholas Cullen 1, Oskar Hansson 1, Sebastian Palmqvist 1
1Lund University - Lund (Sweden), 2Cogstate - London (United Kingdom)

P57  The Amsterdam Instrumental Activities of Daily Living Questionnaire: Validation of a clinically meaningful outcome measure in asymptomatic and early symptomatic Alzheimer’s disease
Mark Dubbelman 1, Merel Postema 1, Philip Scheltens 1, Wiesje Van Der Flier 1-2-3, Sietske Sikkes 1-3
1Alzheimer Center Amsterdam, Department Of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam Umc - Amsterdam (Netherlands), 2Department of Epidemiology and Biostatistics, Amsterdam Umc - Amsterdam (Netherlands), 3Department of Clinical, Neuro- & Developmental Psychology, Vrije Universiteit Amsterdam - Amsterdam (Netherlands)

P58  Monthly at-home computerized cognitive testing to detect diminished practice effects in preclinical Alzheimer’s disease
Roos J. Jutten 1, Dorene M. Rentz 1-2, Rebecca E. Amariaglio 1-2, Rachel F. Buckley 1-2-3, Michael J. Properzi 1, Paul Maruff 4-5, Craig E. Stark 6, Michael A. Yassa 4, Keith A. Johnson 1, Reisa A. Sperling 1-2, Kathryn V. Papp 7-2
1Department Of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (USA), 2Department Of Neurology, Brigham and Women’s Hospital, Harvard Medical School - Boston (USA), 3Melbourne School of Psychological Sciences, University of Melbourne - Melbourne (Australia), 4The Florey Institute Of Neuroscience And Mental Health - Melbourne, Vic (Australia) - Melbourne (Australia), 5Cogstate Ltd. - Melbourne (Australia), 6University Of California, Irvine - Irvine (USA), 7Department Of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (USA)

P59  Use of app-based cognitive assessments during the COVID-19 pandemic: adherence and acceptability among cognitively normal older adults
Louisa Thompson 1, Karra Harrington 2, Nelson Roque 3, Jennifer Strenger 1, Stephen Correia 1, Richard Jones 1, Stephen Salloway 1, Martin Slivinski 2
1Brown University Medical School - Providence (USA), 2Penn State University - University Park (USA), 3University Of Central Florida - Orlando (USA)
POSTERS presented onsite

LP19  Boston Cognitive Assessment (BOCA) — a comprehensive self-administered smartphone- and computer-based at-home test for longitudinal tracking of cognitive performance
Andrey Vyshedskiy  
Boston University - Boston (United States)

LP20  Daily Boston Remote Assessment for Neurocognitive Health (BRANCH): Generating Short-Term
Daniel Soberanes 1, Stephanie Hsieh 2, Olivia Schneider 1, Rachel Buckley 3, Michael Properi 2, Emma Weizenbaum 2, Dorene Rentz 3, Keith Johnson 3, Reisa Sperling 3, Rebecca Amargioli 3, Kathryn Papp 3
1Brigham and Women’s Hospital - Boston (United States), 2Massachusetts General Hospital - Boston (United States), 3Harvard Medical School - Boston (United States)

LP21  Amyloid pathology but not ApoE4 status is permissive for tau-related hippocampal dysfunction
Emrah Duzel 1, Gabriel Ziegler 1, Hartmut Schutze 1, David Berron 1, Anne Maass 2, Glanz Wenzel 1, Michael Buryn 1, Martin Reuter 2, Anika Spottke 3, Anja Schneider 2, Frederic Brosseron 2, Michael Heneka 2, Christoph Laske 3, Oliver Peters 4, Josef Friller 4, Stefan Teipel 4, Ingo Kliman 5, Jens Wiltfang 6, Michael Wagner 7, Frank Jessen 7
1Dzne, Magdeburg - Magdeburg (Germany), 2Dzne, Bonn - Bonn (Germany), 3Dzne, Tübingen - Tübingen (Germany), 4Dzne, Berlin - Berlin (Germany), 5Dzne, Rostock - Rostock (Germany), 6Dzne, Göttingen (Germany), 7Dzne, Bonn/Cologne (Germany)

THEME Epidemiology and clinical trials

P61  Estimates of Frontotemporal Dementia by geographic regions
Cai Gillis 1, Flavia Nery 1, Ellen Huang 1, Elena Ratti 1, Dana Flanders 2, Cathy Lally 3
1Biogen - Cambridge, MA (USA), 2Emory University, Rollins School Of Public Health, Atlanta, Ga (USA), 3Epidemiologic Research & Methods, Llc - Atlanta, Ga (USA)

P63  Distribution and baseline characteristics of participants with rapid progressing Alzheimer's Disease as measured by CDR-SB over 78 weeks in the National Alzheimer's Coordinating Center (NACC)
Cai Gillis 1, Nancy Maserejian 1, Ryan Miller 1
Biogen - Cambridge, MA (USA)

P64  OPTRISE: Population-based screening over SPeech for Clinical Trials in AD
Alexandra König 1, Nicklas Linz 2, Craig Ritchie 3, Stefan Teipel 4, Bruno Dubois 5, Stephanie Bombois 6, Marc Teichmann 7, Sebastian Palmqvist 8, Oskar Hansson 9
1Institut National De Recherche En Informatique Et En Automatique (inria). Stars Team. Sophia Antipolis. Valbonne. France. - Valbonne (France), 2Ks: elements, Saarbrücken, Germany. - Saarbrücken (Germany), 3Edinburgh Dementia Prevention, University Of Edinburgh, Edinburgh, Uk. - Edinburgh (United Kingdom), 4German Center For Neurodegenerative Diseases (dzne), Rostock, Germany; Department Of Psychosomatic And Psychotherapeutic Medicine, University Of Rostock, Rostock, Germany. - Rostock (Germany), 5Hopital Universitaire Pitié Salpêtrière, Institut De La Mémoire Et De La Maladie D alzheimer – Im2a, Paris, France. - Paris (France), 6Clinical Memory Research Unit, Department Of Clinical Sciences, Malmö, Lund University, Lund, Sweden - Lund (Sweden)

P65  Optimizing paths for efficient use of digital health technologies in PD clinical trials: The Critical Path for Parkinson’s 3D6 initiative
Derek Hill 1, Martijn Müller 1, Jesse Cedarbaum 2, Josh Cosman 3, Lauren Oliva 3, Mark Frasier 3, Marissa Dockendorf 4, Ariel Dowling 4, Kirsten Taylor 5, Emily Kunka 6, Caldeira Caldeira 7, Ray Dorsey 8, Diane Stephenson 9
1University College Of London - London (France), 2Critical Path Institute - Tucson (USA), 3Coeurules Clinical Sciences - Woodbridge (USA), 4Abbvie - Cambridge (USA), 5Biogen - Cambridge (USA), 6The Michael J. Fox Foundation - New York (USA), 7Merc - Philadelphia (USA), 8Blakeda - Social Circle (USA), 9Roche - Basel (Switzerland), 10UCb - San Francisco (USA), 11Lundbeck - Copenhagen (Denmark), 12University Of Rochester - Rochester (USA)
POSTERS presented onsite

P66 Reducing sources of variability of Digital Health Technologies in clinical trials by adding environmental context
Derek Hill 1, Tri Than Ham Tran 1, Nicolas Defranoux 1, Alizee Devaux 1, Souleymen Sahnoun 1
Panoramic Digital Health - Grenoble (France)

P67 Remote self-administration of cognitive tests in older adults with and without subjective cognitive decline using the BAC tablet-based ePRO platform
Alexandra Atkins 1, Mike Kraus 1, Matthew Welch 1, Joshua Yuan 1, Heather Stevens 1, Philip Harvey 2, Kathleen Welsh-Bohmer 3, Richard Keefe 3, 4
1Verasci - Durham (USA), 2University Of Miami Miller School Of Medicine - Miami (USA), 3Verasci - Durham (USA minor outlying islands) - Durham (USA), 4Duke University Medical Center - Durham (USA), 5Verasci - Durham (USA) - Durham (USA minor outlying islands)

LP24 Evaluation of a remote speech-based AI system for detection of amyloid-confirmed prodromal Alzheimer’s disease
Emil Fristed 1, Caroline Skirrow 1, Marton Meszaros 1, Lenain Raphael 1, Udeepa Meepegama 1, Jack Weston 1
Novoci - London (United Kingdom)

LP25 AI-Driven Physician Referral Network Recruitment Initiative to Drive Volume, Speed and Efficiency for Clarity AD, a Phase 3 Trial in Early AD (ClarityAD)
Michael Stalder 1, Seth Goodman 1, Erin Beck 1, Russel Harris 1, Kate Tranotti 1, Chad Swanson 2
1SiteRx Inc. - New York, NY (United States), 2Eisai Inc. - Woodcliff Lake, NJ (United States)

LP26 A First Look at Telemedicine Use for Pre-Screening in Alzheimer’s Disease Clinical Trials During a Global Pandemic
Jennifer Mitolo 1, Elly Lee 1, Razyya Abdulmumin 1, Catherine Eng 1, Ralph Lee 1, Brenda Martinez 1
Irvine Clinical Research - Irvine (United States)

THEME
Health economics and clinical trials

P68 Staying sharp beyond the age of 65 years: A social marketing approach to the promotion of cognitive health in Luxembourg
Mathilde Barbier 1, Anna Elena Kornadt 1, Carine Federspiel 1, Jean-Paul Steinmetz 2, Claus Vögele 1
1University Of Luxembourg - Esch-Sur-Alzette (Luxembourg), 2Zitha - Luxembourg (Luxembourg)

P69 Understanding Treatment Goals for Patients and Caregivers with Alzheimer’s Disease along the Continuum of the Disease Consideration in Clinical Trial Design
David Gomez-Ulloa D 1, M Chris Runken 2, Wilton I Rodriguez 2, Basilio Hernandez 1, E Anne Davis 1, Paul Nisbet 4
1Grifols - Sant Cugat Del Valles (Spain), 2Grifols Ssna - Research Triangle Park, Nc (USA), 3Xcenda - Palm Harbor (USA), 4One Research, Llc - Charleston, Sc (USA)

LP27 Estimation of Long-term Care Utilization and Lifetime Distribution of Medical Cost for Dementia in Korea
Jun Hong Lee 1
National Health Insurance Service Ilsan Hospital - Goyang-Si (Korea, Republic of)

THEME
New therapies and clinical trials

P70 Phase I single (SAD) and Multiple Ascending Dose (MAD) studies evaluating the safety, tolerability Pharmacokinetics (PK) and Pharmacodynamics (PD) of YTX-7739, a novel brain penetrant small molecule SCD inhibitor, in healthy subjects
Ajay Verma 1, Brigitte Robertson 1
Yumanity Therapeutics - Boston (USA)

P71 Design of INFRONT-3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL001 IN FTD-GRN
Sam Jackson 1, Michael Ward 1, Yijie Liao 1, Brian Mangal 1, Felix Yeh 1, Whedy Wang 1, Robert Paul 1
Alector - South San Francisco, Ca (USA)

P72 External Counterpulsation (Renew™ NCP-5 Device) for the Treatment of MCI due to Alzheimer’s Disease or Mild Dementia of the Alzheimer’s Type: A Pivotal Trial
Patrick Monarto 1, Lauryn Gorby 1, David Salat 1, Jeffrey Burns 2, Tom Moreno 4, Jonathan Helfgott 1
1University Of Kansas Medical Center - Kansas City (USA), 2Harvard Medical School - Boston (USA), 3Kansas University Alzheimer’s Disease Center - Kansas City (USA), 4Renew Research - Farmington Hills (USA)

LP28 A Phase 1a, Randomized, Placebo-controlled, Single and Multiple Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of Novel Regenerative Therapeutic NNI-362
Judith Kelleher-Anderson 1, Esther Yoon 1, Carol Green 3, Claire McFarlane 3, Raymond Turner 4
1Neuromactent, Inc. - Mountain View (United States), 2California Clinical Trials Medical Grp - Glendale (United States), 3Sri - Menlo Park (United States), 4Georgetown University - Washington, D.c. (United States)
\textbf{LP29} \textit{BET-inhibition by Apabetalone and Cognitive Effects: A Prespecified MoCA Analysis Nested in the BETonMACE Randomized Controlled Trial}

Jeffrey Cummings 1, Gregory Schwartz 2, Stephen Nicholls 3, Aziz Khan 4, Christopher Halliday 5, Peter Toth 6, Michael Sweeney 6, Jan Johansson 6, Norman Wong 6, Ewelina Kulikowski 6, Kamyar Kalantar-Zadeh 6, Kenneth Lebioda 6, Henry Ginsberg 8, \textbf{Bengt Winblad} 9, Henrik Zetterberg 10, 11, 12, Kausik Ray 13

1Chambers-Grundy Center For Transformative Neuroscience, Department Of Brain Health, School Of Integrated Health Sciences, University Of Nevada Las Vegas (unlv) - Las Vegas (United States), 2Division Of Cardiology, University Of Colorado School Of Medicine - Denver (United States), 3Victorian Heart Institute, Monash University - Melbourne (Australia), 4Resverlogix Corp. - Calgary (Canada), 5Ciccarone Center For The Prevention Of Cardiovascular Disease, Johns Hopkins University School Of Medicine - Baltimore (United States), 6Resverlogix Corp. - California (United States), 7Department Of Nephrology And Hypertension, University Of California Irvine - California (United States), 8Department Of Medicine, Vagelos College Of Physicians And Surgeons, Columbia University, New York, Ny Department Of Neurobiology - New York (United States), 9Care Sciences And Society, Center For Alzheimer Research, Division Of Neurogeriatrics, Karolinska Institutet, Solna, Sweden, And Karolinska University Hospital, Theme Inflammation And Aging, Huddinge - Stockholm (Sweden), 10Department Of Psychiatry And Neurochemistry, Institute Of Neuroscience And Physiology, The Sahlgrenska Academy At The University Of Gothenburg - Molndal (Sweden), 11Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Molndal (Sweden), 12UK Dementia Research Institute at UCL and Department of Neurodegenerative Disease, UCL Institute of Neurology - London (United Kingdom), 13Imperial Centre For Cardiovascular Disease Prevention, Imperial College - London (United Kingdom)

\textbf{LP31} \textit{Novel therapeutic efficacy of Galectin-3 antibody for treating Alzheimer’s disease}

Suhail Rasool 1, Pooja Patel 1, Jenny Johansson 1, Taufeq Ahmed 1, Ludmila Voloboueva 1, Sangmi Lee 1, Catherine Gordon 1, Kyungjoon Lee 1, Dongxu Sun 1

1Truebinding Inc. - Foster City (United States)

\textbf{THEME}

\textbf{Proof of concept/Translational research for Alzheimer Drug Development interventions}

\textbf{P73} \textit{Alzheimer’s disease prevention Within Reach by 2025: Targeted-Risk-AD-Prevention (TRAP) Strategy}

Francesca Vitali 1, 2, 3, Gregory L. Branigan 1, 4, 5, Roberta D. Brinton 1, 4, 6

1Center For Innovation In Brain Science, University Of Arizona - Tucson (USA), 2Department of Neurology, University of Arizona - Tucson (USA), 3Center for Biomedical Informatics and Biostatistics, University of Arizona - Tucson (USA), 4Department of Pharmacology - Lawrence (USA), 5MD-PhD training program, College of Medicine, University of Arizona - Tucson (USA), 6Department of Pharmacology - Tucson (USA)

\textbf{LP32} \textit{Probing Gut-Brain Links in Alzheimer's Disease with Rifaximin}

Paul Suhocki 1, James Ronald 1, Anna Mae Diehl 1, David Murdoch 1, Murali Doraiswamy 1

1Duke University - Durham (United States)
Conference Room
All sessions will take place in the Grand Ballroom A.

Coffee Breaks and Poster Sessions
Breaks and poster presentations will be held in the Statler Room across from Grand Ballroom A.
Meet our poster presenters during the coffee breaks. A poster assistance desk will be available to locate the posters.

Lunch boxes*: To be picked up in the ABC room (only for attendees who purchased the lunch package beforehand).
*Please note that there is no possibility of buying lunches onsite.

Speaker Ready Room – Preview room – Hours of Operation
- Tuesday, November 9: 1 pm to 6 pm
- Wednesday, November 10: 7 am to 7 pm
- Thursday, November 11: 7 am to 7 pm
- Friday, November 12: 7 am to 3 pm

Hosted Receptions and Networking Time
Signage will direct you to public receptions every evening.

Networking coffee time
In addition to the regular coffee breaks we suggest that you enjoy a cup of coffee with your peers and increase your networking time around the conference starting times:
- Tuesday, November 9: 3:15 pm to 4:00 pm
- Wednesday, November 10: 7:30 am to 8:00 am
- Thursday, November 11: 7:30 am to 8:00 am
- Friday, November 12: 7:30 am to 8:00 am

FREE WIFI available at CTAD
Network: CTAD21 – Password: CTAD21
CTAD would like to thank its 2021 Gold partners for their continued support.
November 29 - December 2, 2022
San Francisco, USA

www.ctad-alzheimer.com
Email: ctad@ant-congres.com
SUMMARY

Scientific program

Poster presented remotely
SYMPOSIA

RS1 Cannabinoids for neuropsychiatric symptoms of Alzheimer’s: trial designs and outcomes
Chair: Paul Rosenberg, Johns Hopkins Hospital, Baltimore, MD (USA)

Nabilone for the treatment of agitation in Alzheimer’s disease
Krista Lanctôt, Sunnybrook Research Institute - Toronto (Canada)

Assessing the efficacy and safety of synthetic THC (Dronabinol) for agitation and CBD for anxiety in Alzheimer’s dementia
Brent Forester, McLean Hospital - Belmont, MA (USA)

Life’s end Benefits of CannaBidol and TetraHydrocannabinol (LiBBY) Trial
Jacobo Mintzer, Roper St. Francis Healthcare, Charleston, SC (USA)

RS2 The Next Generation of Speech Biomarkers for the Early Detection of Alzheimer’s Disease
Chair: Emil Fristed, Novoic - London (United Kingdom)

Validation of a novel fully automated story recall task for repeated remote high-frequency administration
Caroline Skirrow, Novoic, Bristol (United Kingdom)

How clinically informed deep learning can make better speech biomarkers
Jack Weston, Novoic - London (United Kingdom)

A harmonized speech dataset for Alzheimer’s disease biomarker development: study design of the Diagnostics Accelerator Speech Consortium Study
Lamplos Kourtis, Tufts University Medical Center, Gates Ventures, Circadic – Boston, MA (USA)

RS3 Back to the Future: Emerging Opportunities to Treat Basal Forebrain Cholinergic Neuron (BFCN) Dysfunction in Alzheimer’s Disease (AD)
Chair: Marwan Sabbagh, Cleveland Clinic Lou Ruvo Center For Brain Health Las Vegas, NV, (USA)

The Contribution of BFCN Dysfunction and Degeneration to Disease Expression and Progression in AD
Ole Isacson, Neuroregeneration Research Institute at Mclean Hospital - Belmont and Harvard Medical School - Boston, MA (USA)

Mechanisms of, and Preclinical Results with Novel Approaches to Treating, BFCN Dysfunction and Degeneration
Ralph Nixon, Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research - Orangeburg and NYU Langone Health - New York, NY (USA)

Clinical Results with Novel Approaches that Reverse BFCN Dysfunction
John Alam, EIP Pharma, Inc. – Boston, MA (USA)

LATE BREAKING ORAL COMMUNICATIONS

LBRI - The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
Giovanni Frisoni 1, Daniele Altomare 1, Dietmar Thal 1, Federica Ribaldi 1, Rik Van Der Kant 2, Rik Ossenkoppele 2, Kaj Blennow 4, Jeffrey Cummings 5, Cornelia Van Duijn 6, Peter M. Nilsson 7, Pierre-Yves Dietrich 6, Philip Scheltens 2, Bruno Dubois 9
1University Of Geneva - Geneva (Switzerland), 2University Of Leuven - Leuven (Belgium), 3Amsterdam Umc - Amsterdam (Netherlands), 4University Of Gothenburg - Gothenburg (Sweden), 5University Of Nevada Las Vegas - Las Vegas (United States), 6Erasmus University Medical Center - Rotterdam (Netherlands), 7Skåne University Hospital - Malmö (Sweden), 8Geneva University Hospitals - Geneva (Switzerland), 9Sorbonne Université - Paris (France)
LBR2 - Baseline Embark data from Emerge, Engage, and Prime participants in the Embark re-dosing study
Sharon Cohen 1, Christopher Van Dyck 2, Catherine Mummary 3, Anton Porsteinsson 4, Jessica Kong 5, Ryan Miller 5, Annie Racine 5, John O’gorman 6, Samantha Budd Haeberlein 5, Salloway Stephen 6
1Toronto Memory Program - Toronto (Canada), 2Alzheimer’s Disease Research Unit, Yale School Of Medicine - New Haven (United States), 3Department Of Neurology, Mayo Clinic - Rochester (United States), 4Alzheimer’s Therapeutic Research Institute, University Of Southern California San Diego - San Diego (United States), 5University Of California, Irvine - Irvine (United States), 6Massachusetts General Hospital, Harvard Medical School - Boston (United States)

LBR3 - National Alzheimer’s Disease Clinical Trial Sites’ Accommodations to the COVID-19 Pandemic
Elizabeth Rhodes 1, Paul Aisen 2, Joshua Grill 3, Dorene Rentz 4,5, Reisa Sperling 4,5, Ronald Petersen 4, Stephen Salloway 7, Doris Pierce 8, Rema Raman 9
1Washington University School Of Medicine, Department Of Neurology - St. Louis (United States), 2Department Of Radiology And Nuclear Medicine, Amsterdam Neuroscience, Amsterdam Umc, Vrije Universiteit - Amsterdam (Netherlands), 3Section Of Neuroradiology, Vall D’hebron University Hospital - Barcelona (Spain), 4Advanced Clinical Imaging Technology, Siemens Healthcare - Lausanne (Switzerland), 5Wake Forest School Of Medicine - Winston-Salem (United States), 6Department Of Neurology, Mayo Clinic - Rochester (United States), 7Butler Hospital And Brown University - Providence (United States), 8Eastern Kentucky University - Richmond (United States), 9Alzheimer's Therapeutic Research Institute, University Of Southern California, San Diego - San Diego (United States)

LBR4 - Defining a standardized MRI acquisition protocol to be proposed to ICARE AD-US sites for baseline and ARIA monitoring
Tammie, L. S. Benzinger 1, Frederik Barkhof 2, Alex Rovira 3, Tobias Kober 4, Christopher, T. Whittlow 5, Michael Smith 6, Christina, M. Grassi 6, Elizabeth Fisher 6
1Washington University School Of Medicine, Department Of Neurology - St. Louis (United States), 2University Of California, Irvine - Irvine (United States), 3Massachusetts General Hospital, Harvard Medical School - Boston (United States), 4Brigham and Women’s Hospital, Harvard Medical School - Boston (United States), 5Department Of Neurology, Mayo Clinic - Rochester (United States), 6Butler Hospital And Brown University - Providence (United States), 7Eastern Kentucky University - Richmond (United States), 8Alzheimer’s Therapeutic Research Institute, University Of Southern California, San Diego - San Diego (United States)

LBR5 - Top-line results from TANGO, a Phase 2 study of gosuranemab in participants with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease
Melanie Shulman 1, Raj Rajagovindan 1, Jessica Kong 1, John O’gorman 1, Louis Viollet 1, Ellen Huang 1, Heike Hering 1, Elena Ratti 1, Danielle Graham 1, Samantha Budd Haeberlein 1
1Eisai Ltd. - Hatfield (United Kingdom), 2C 2 N Diagnostics - St. Louis (United States), 3Protelos AB - Stockholm (Sweden), 4Eisai (United States), 5Eisai (United States), 6Eisai (United States)

LBR6 - Oral treatment with OLX-07010, a small molecule inhibitor of tau self-association, reduced tau aggregation to baseline in a therapeutic study of aged tau P301L JNPL3 mice
James Moe 1, Patricia Lopez 2, Heidy Jimenez-Bravar 3, Adrien Leslie 4, J Eun 5, Adam Wolin 4, Jeremy Koppel 4, Peter Davies 4, Dhruv Patel 5, Eliot Davidowitz 2
1Oligomerix, Inc. - White Plains (United States), 2Oligomerix, Inc. - Bronx (United States), 3Feinstein Institutes For Medical Research - Manhasset (United States), 4Innate Immunotherapeutics - Cambridge (United States)

LBR7 - Analyzing the CSF proteome to support decisions in an AD clinical trial program
Jan Pike 1, Sasa Koncarevic 2, Juliane Weisser 2, Michael Bremang 2, R J Tesi 3, C J Barnum 3
1Proteome Sciences Plc - London (United Kingdom), 2Proteome Sciences R&D GmbH & Co Kg - Frankfurt (Germany), 3Inmunebio - Boca Raton (United States)

LBR8 - Prediction of brain amyloid pathology using plasma Aβ42/40 ratio measured using the C2N PrecivityADTM test in the Mission AD study samples
David Verbel 1, Michelle Gee 2, June Kaplow 1, Michio Kanekiyo 1, Michael Irizarry 1, Shobha Dhadda 1, Akihiko Koyama 1, Tim West 3, Matt Meyer 3, Kris Kirmess 2
1Eisai Inc. - Woodcliff Lake (United States), 2Eisai Ltd. - Hatfield (United Kingdom), 3C 2 N Diagnostics - St. Louis (United States)

LBR9 - Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD – a MissionAD tau sub-study
Santiago Bullich 1, Andre Mueller 1, Susan De Santi 2, Norman Koglin 1, Stephen Krause 2, June Kaplow 2, Michio Kanekiyo 2, Núria Roé-Vellvé 1, Audrey Perrottin 1, Aleksandar Jovalekic 1, David Scott 1, Michelle Gee 2, Andrew Stephens 1, Michael Irizarry 2
1Life Molecular Imaging (Germany), 2Eisai (United States), 3Bioclinica (United States)
LBR10 - The impact of the COVID-19 pandemic on cognitive health
Helen Brooker 1, Vincent Hayman 2, Dag Aarsland 3, Byron Creese 4, Clive Ballard 2, Anne Corbett 2
1 Exeter University Medical School - Exeter (United Kingdom), 2 Exeter University Medical School - Exeter (United Kingdom), 3 Department Of Old Age Psychiatry, Institute Of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King’s College London - London (United Kingdom)

LBR11 - Utility of plasma Aβ1–42/Aβ1–40 as a screening tool is limited due to lack of robustness
Christina Rabe 1, Tobias Bittner 1, 2, Alexander Jethwa 3, Ivonne Suridjan 4, Ekaterina Manuilova 3, Henrik Zetterberg 5, 6, 7, Kaj Blennow 5, 6, 9
1 Genentech, Inc. - South San Francisco (United States), 2 F. Hoffmann-La Roche Ltd - Basel (Switzerland), 3 Roche Diagnostics GmbH - Penzberg (Germany), 4 Roche Diagnostics International Ltd - Rotkreuz (Switzerland), 5 Department Of Psychiatry And Neurochemistry, Institute Of Neuroscience And Physiology, The Sahlgrenska Academy At The University Of Gothenburg - Mölndal (Sweden), 6 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), 7 Department of Neurodegenerative Disease, UCL Institute of Neurology and UK Dementia Research Institute at UCL - London (United Kingdom), 8 Clinical Memory Research Unit, Department Of Clinical Sciences Malmö, Lund University - Malmö (Sweden), 9 Memory Clinic, Skåne University Hospital - Malmö (Sweden)

LBR12 - Polygenic risk scores can predict early cognitive impairment as measured by the Preclinical Alzheimer Cognitive Composite (PACC) score in the ADNI cohort
Qian Gao 1, Richard Pither 1, Paula Daunt 1, Alex Gibson 1
Cytox Ltd - Oxford (United Kingdom)

LBR13 - Association of serum degraded tau biomarkers with preclinical dementia: a Mendelian randomization study
Tobias Melton Axelsen 1, 2, 3, Cecilie Liv Bager 4, Morten Asser Karsdal 4, Kim Henriksen 4, Man-Hung Eric Tang 4
1 Sanos Clinic - Herlev (Denmark), 2 Department of Biomedical Science - Copenhagen (Denmark), 3 Nordic Bioscience A/S - Herlev (Denmark), 4 Nordic Bioscience A/S - Herlev (Denmark)

LBR14 - 18F-APN-1607 Tau PET in Progressive Supranuclear Palsy-Like Symptoms Caused by TBK1 Mutations
Feng-Tao Liu 1, Tzu-Chen Yen 2, Chuan-Tao Zuo 1, Chen Yan 1, Jian Wang 1
1 Huashan Hospital, Fudan University (China), 2 Aprinoia Therapeutics Co., Ltd, Suzhou (China)
RS4 Innovative Approaches and Technologies Shaping the Future of Alzheimer’s Clinical Trials
Chair: Jeffrey Cummings, University of Nevada - Las Vegas, NV (USA)

Prognostic Covariate Adjustment (PROCOVA) enables smaller, more powerful trials while reducing uncertainty and maintaining control of type I error
Alejandro Schuler, Unlearn.ai, Stanford University - San Francisco, CA (USA)

Design and implementation of novel trial designs: Harnessing short-term learning curves (STLCs) to accelerate early detection and tracking in Alzheimer’s disease secondary prevention trials
Kathryn Papp, Harvard Medical School; Brigham And Women’s Hospital – Boston, MA (USA)

Design and implementation of novel trial approaches: New imaging markers for clinical trials
Steven Chance, Oxford Brain Diagnostics - Oxford (United Kingdom)

ROC1 - Comparing remote versus in-clinic clinical outcome assessments in the Tauriel study of semorinemab in early AD: The COVID-19 experience
Paul Manser 1, Mira Blendstrup 1, Nia Sengupta 1, Karen Pickthorn 1, Enrique Gaspar 2, Winnie Leung 1, Mayumi Thompson 1, Edmond Teng 1, Rajesh Menon 1
1Genentech, Inc. - South San Francisco, CA (USA), 2Medavante-Prophase - Hamilton, NJ (USA)

ROC2 - The utility of using version 3 of the Alzheimer's Disease Research Centers' neuropsychological test battery for prevention trials
Kwun Chuen Gary Chan 1, Hiroko H. Dodge 2, Lisa L. Barnes 3, Fan Xia 4, Walthier A. Kukull 4, Andrew J. Saykin 5
1University Of Washington-Seattle, WA (USA), 2Oregon Health And Science University – Portland, OR (USA), 3Rush University – Chicago, IL (USA), 4University of Washington – Seattle, WA (United States), 5Indiana University - Indianapolis, IN (USA)

ROC3 - Allopregnanolone as a Regenerative Therapeutic for Alzheimer's: Exploratory Phase 1 Neuroimaging MRI Outcomes
Adam C. Raikes 1, Dawn Matthews 2, Gerson Hernandez 1, Yonggang Shi 3, Meng Law 4, Lon Schneider 5, Roberta Brinton 1
1Center For Innovation In Brain Science, University of Arizona – Tucson, AZ (USA), 2ADM Diagnostics, Inc – Northbrook, IL (USA), 3USC Stevens Neuroimaging and Informatics Institute, University of Southern California - Los Angeles, CA (USA), 4Monash University - Melbourne (Australia), 5Keck School Of Medicine of The University Of Southern California - Los Angeles, CA (USA)

ROC4 - Early detection of Alzheimer’s disease with BrainSee, the FDA Breakthrough software medical device
Thomas Liebmann 1, Elham Khosravi 2, Pavan Krishnamurthi 3, Padideh Kamali-Zaere 2, Kaveh Vejdani 3
1Darmiyan, Inc. - Penzberg (Germany), 2Darmiyan, Inc. - Berlin (Germany), 3Darmiyan, Inc. - San Francisco, CA (USA)

ROC5 - Evaluating the contribution of image-derived features for predicting rate of cognitive decline in a large cohort (including 6 clinical trials; n=3,339) of early AD patients
Derrek Hibar 1, Balazs Toth 1, Christopher Galli 2, Tobias Bittner 2, Christina Rabe 1, David Clayton 1
1Genentech - South San Francisco, CA (USA), 2Roche - Basel (Switzerland)

ROC6 - Assessing 11β-HSD1 in vivo occupancy by Xanamem® using 11C-TARACT PET
Christopher C. Rowe 1, Victor L. Villemagne 2, Vincent Doré 2, Lee Chong 1, Rachel Mulligan 1, Svetlana Bozinovski 1, Rodney Guzman 1, Michael Kassiou 4, Jack Taylor 5, Tamara Miller 5
1Austin Health - Melbourne (Australia), 2University of Pittsburgh – Pittsburgh, OH (USA), 3Csiro - Melbourne (Australia), 4University Of Sydney - Sydney (Australia), 5Actinogen Medical Ltd - Sydney (Australia)
ROC8 - Characteristics of subjects with discordant amyloid status between visual read and centiloid from the Phase 2 clinical study of Tilavonemab in early Alzheimer’s disease
Eddie Stage 1, Dustin Wooten 1, Ziyi Jin 1, Charles Locke 1, Jacob Hesterman 2, John Seibyl 2, Hana Florian 1, Robert Comley 1, Qi Guo 1
1Abbvie Inc. - North Chicago (United States), 2Invicro - New Haven (United States)

ROC10 - Plasma Neurofilament Light chain and Phosphorylated tau217 in Patients with Type 2 Diabetes Treated with GLP-1 Receptor Agonist Dulaglutide in the REWIND Cardiovascular Outcomes Trial
Jonathan M Wilson 1, Hui-Rong Qian 1, Courtney Irelan 1, Hannah Badger 1, Jeffrey L Dage 1, Kevin L Duffin 1, Dawn A Brooks 1, Hertzel C Gerstein 2, M Angelyn Bethel 1
1Eli Lilly and Company – Indianapolis, IN (USA), 2Population Health Research Institute - Hamilton (Canada) - Hamilton (Canada)
Program

Thursday, NOVEMBER 11

Presentations will be available from 8:00 am USA Eastern Standard Time

ORAL COMMUNICATIONS

ROC11 - Maximizing precision and power in Alzheimer’s disease trials: how and when to select the most prognostic baseline variables
Michael Rosenblum 1, Elizabeth Colantuoni 1, Melody Dehghan 1, Michela Gallagher 1, Arnold Bakker 1
Johns Hopkins University – Baltimore, MD (USA)

ROC12 - Baseline characteristics of the GRADUATE studies: Phase III randomized, placebo-controlled studies investigating subcutaneous gantenerumab in participants with early Alzheimer’s disease
Christopher Lane 1, Szofia Bullain 2, Monika Baudler 2, Angeliki Thanasopoulou 2, Paul Delmar 2, Mercè Boada 3, 4, Timo Grimmer 5, Diana Kerwin 6, Paolo Fontoura 7, Geoffrey A Kerchner 2, Rachelle S Doody 7
1Roche Products Ltd - Welwyn Garden City (United Kingdom), 2F. Hoffmann-La Roche - Basel (Switzerland), 3Fundació Ace, Barcelona Alzheimer Treatment And Research Center - Barcelona (Spain), 4Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III - Madrid (Spain), 5Klinikum Rechts Der Isar, Technical University Of Munich, School Of Medicine · Munich (Germany), 6Kerwin Medical Center – Dallas, TX (USA), 7Genentech, Inc. - South San Francisco, CA (USA)

ROC13 - T2 Protect AD: Results of a 48-Week Randomized Clinical Trial of Toriluzole in Mild-to-Moderate Alzheimer’s Disease
Howard Feldman 1, Qiu Yuqi 1, Karen Messer 1, Stephen Kaplita 2, Ronald Thomas 1, Branko Huisa-Garate 1, James Brewer 1, Lida Donahue 2, Vladimir Coric 2, Brianna Askew 1, Gregory Jicha 3, Christopher Van Dyck 4, Mark Brody 5, Jonathan Drake 6, Gabriel Leger 1, Anton Porsteinsson 7, Suzanne Hendrix 8, Diane Jacobs 1, David Salmon 1, Irfan Qureshi 2
1University Of California San Diego - La Jolla, CA (USA), 2Biohaven Pharmaceuticals - New Haven, CT (USA), 3University Of Kentucky College of Medicine · Lexington (USA), 4Yale University School of Medicine · New Haven, CT (USA), 5Brain Matters Research - Delray Beach, FL (USA), 6Alzheimer’s Disease And Memory Disorders Center at Rhode Island Hospital – Providence, RI (USA), 7University Of Rochester School Of Medicine And Dentistry – Rochester, MN (USA), 8Pentara Corporation – Millcreek, UT (USA)

ROC14 - Brainshuttle AD: A Phase Ib/IIa Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6102 in Participants with Prodromal or Mild-to-Moderate Alzheimer’s Disease
Luka Kulic 1, Annamarie Vogt 1, Fabien Alcaraz 1, Philip Barrington 1, Maddalena Marches 1, Gregory Klein 1, Ruth Croney 1, David Agnew 1, João A Abrantes 1, Paul Jordan 1, Hanno Svoboda 1
F. Hoffmann-La Roche Ltd - Basel (Switzerland)

ROC15 - PK/PD modeling framework to inform the clinical development of RG6102, an amyloid-targeting investigational drug with enhanced brain penetration properties
João A Abrantes 1, Hans Peter Grimm 1, Carsten Hofmann 1, Simon Buatois 1, Sébastien Jolivet 1, Nicolas Frey 1, Hanna Silber Baumann 1, Hanno Svoboda 1, Luka Kulic 1
Roche Innovation Center - Basel (Switzerland)

ROC16 - Results of A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB076 in Healthy Volunteers and Subjects With Alzheimer’s Disease
Elena Ratti 1, Hua Carroll 1, Lin Lin 1, Carrie Rubel 1, Alexis Ang 1, John O’gorman 1, Matthew Ross 1, Kumar Kandadi Muralidharan 1, Danielle Graham 1, Julie Czerkowicz 1, Ellen Huang 1, Jaren Landen 1, Samantha Budd Haeberlein 1
Biogen - Cambridge (United States)
Characterization of the disease course during transitioning from MCI due to AD to dementia predicts follow-up

Johannes Streffer 1, 2, Bénédicte Le 1, Olivier Sol 1, Marija Vukicevic 1, Emma Fiorini 1, Eva Gollwitzer 1, Valérie Hliva 1, Julien Mermoud 1, David Hickman 1, Julian Gray 1, Antonio Melo Dos Santos 1, Nicolas Piot 1, Julien Rongère 1, Andrea Pfeifer 1, Marie Kosco-Vilbois 1, Philip Scheltens 3

1AC Immune - Lausanne (Switzerland), 2Department of Biomedical Sciences, University of Antwerp - Antwerpen (Belgium), 3VUMC - Amsterdam (Netherlands)

ROC18 - Characterization of the disease course during transitioning from MCI due to AD to dementia predicts follow-up performance and reveals possible contribution of reduced hippocampal atrophy on the intervention effect in the LipiDIet trial

Tobias Hartmann 1, 2, Alina Solomon 3, 4, 5, Pieter Visser 6, 7, Floor Van Oudenhoven 8, 9, 10, Dimitris Rizopoulos 8, 9, Suzanne Hendrix 11, Kaj Blennow 12, 13, Mia Kivipelto 3, 8, 9, 14, Hilka Soininen 3, 14

1Deutsches Institut Für Demenz Prävention (didp), Medical Faculty, Saarland University - Homburg (Germany), 2Department of Experimental Neurology, Saarland University - Saarbrücken (Germany), 3Department Of Neurology, Institute Of Clinical Medicine, University Of Eastern Finland - Kuopio (Finland), 4Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute - Huddinge (Sweden), 5Clinical Trials Unit, Theme Aging, Karolinska University Hospital Kuopio - Huddinge (Sweden), 6Department Of Psychiatry And Neuropsychology, Alzheimer Center Limburg, University Of Maastricht - Maastricht (Netherlands), 7Department of Neurology, Alzheimer Center, VU University Medical Center - Amsterdam (Netherlands), 8Department Of Biostatistics, Erasmus MC - Rotterdam (Netherlands), 9Department of Epidemiology, Erasmus MC - Rotterdam (Netherlands), 10Dario Nutricia Research, Utrecht - Utrecht (Netherlands), 11Pentara Corporation, Milcreek - Millcreek, UT (USA), 12Department Of Psychiatry And Neurochemistry, Institute Of Neuroscience And Physiology, The Sahlgrenska Academy At University Of Gothenburg - Mölndal (Sweden), 13Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), 14Neurocenter, Department of Neurology, Kuopio University Hospital - Kuopio (Finland)

ROC19 - Phase 2 Study of Tilavonemab, an Anti-tau Antibody, in Early Alzheimer’s Disease

Hana Florian 1, Delli Wang 1, Qi Guo 1, Ziyi Jin 1, Nahome Fisseha 1, Beatrice Rendenbach-Mueller 1

Abbvie, Inc. - North Chicago, IL (USA)

ROC20 - The epigenetic modulator apabetalone decreases neuroinflammation in blood brain barrier cell models and LPS-treated mice

Sylwia Wasiak 1, Li Fu 1, Emily Daze 1, Dean Gilham 1, Brooke Rakai 1, Stephanie Stotz 1, Laura Tsuijikawa 1, Christopher Sarsons 1, Ravi Jahagirdar 1, Norman Wong 1, Michael Sweeney 1, Jan Johansson 2, Ewelina Kulikowski 3

1Resverlogix Corp - Calgary (Canada), 2Resverlogix Corp - San Francisco, CA (USA)

ROC21 - Effect of Plasma Exchange with Albumin Replacement in Alzheimer’s Treatment on Ability to Perform Activities of Daily Living (ADL)

Richard B Lipton 1, Walter F Stewart 2, Lauren Podger 3, David Gomez-Ulloa 4, M Chris Runken 3, Miquel Barcelo 4, Carlota Grifols 4, Daniel Serrano 6

1Albert Einstein College Of Medicine - New York, NY (USA), 2Medcurio Inc - Oakland, CA (USA), 3Open Health Group - Marlow (United Kingdom), 4Grifols - Sant Cugat Del Vallès (Spain), 5Grifols Ssna - Research Triangle Park, NC (USA), 6Open Health Group - Bethesda, MD (USA)

ROC22 - Baseline Characteristics for CLARITY-AD: A Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study Evaluating Lecanemab (BAN2401) in Early Alzheimer’s Disease

Shau Yu Lynch 1, Michelle Gee 2, Michio Kanekiyi 1, Tanya Bogoslovsky 1, June Kaplow 1, Shobha Dhadda 1, Michael Irizarry 1, David Li 1, Vicki Taylor 2, Mark Hodgkinson 1, Masaki Nakagawa 2, Chad Swanson 3

1Eisai Inc - Woodcliff Lake (USA), 2Eisai Ltd - Hatfield (United Kingdom), 3Eisai Co., Ltd - Tokyo (Japan)

ROC23 - A Stepwise Tier-Based Approach for Determining Patient Eligibility in CLARITY AD: A Phase 3 Placebo-Controlled, Double-Blind Study to Confirm the Safety and Efficacy of Lecanemab (BAN2401) 10 mg/kg Biweekly in Patients with Early Alzheimer’s Disease

Shau Yu Lynch 1, Michelle Gee 2, Michio Kanekiyi 1, Michael Smith 3, Tanya Bogoslovsky 1, June Kaplow 1, Shobha Dhadda 1, Michael Irizarry 1, Vicki Taylor 2, Mark Hodgkinson 1, Masaki Nakagawa 2, Chad Swanson 3

1Eisai Inc - Woodcliff Lake (USA), 2Eisai Ltd - Hatfield (United Kingdom), 3Worldwide Clinical Trials - Research Triangle (USA), 4Eisai Co., Ltd - Tokyo (Japan)
THEME
AD clinical trials and COVID-19

THEME
Behavioral disorders and clinical trials

THEME
Clinical trials: cognitive and functional endpoints

THEME
Clinical trials: imaging

THEME
Clinical trials: biomarkers including plasma

THEME
Clinical trials: methodology

THEME
Clinical trials: results

THEME
Cognitive assessment and clinical trials

THEME
Digital health/E-trials

THEME
Health economics and clinical trials

THEME
Epidemiology and clinical trials

THEME
New therapies and clinical trials

THEME
Proof of concept/Translational research for Alzheimer Drug Development interventions

---

Posters presented remotely
All posters presented remotely will also be available at all times on the digital platform to be viewed by participants attending remotely or in-person.
THEME
AD clinical trials and COVID-19

RP1 Dementia research participation and patient preferences during the COVID-19 pandemic
Lucianne Dobson 1, Floey Urban 1, Ross Paterson 1, Sebastian Crutch 1, Suzie Barker 1, Cath Mummery 1
Dementia Research Centre, National Hospital For Neurology And Neurosurgery, Queen Square, University College London And University College London Hospital - London (United Kingdom)

THEME
Behavioral disorders and clinical trials

RP3 Pharmacological treatment of neuropsychiatric symptoms of dementia: a network meta-analysis
Jin-Tai Yu, Huashan Hospital, Fudan University - Shanghai (China)

LRP1 Beneficial Effects of Masupirdine on Psychosis in Patients with Alzheimer’s disease, Addressing Limitations of Current Pharmacological Interventions
Ramakrishna Nirogi 1, Anil Shinde 1, Abdul Rasheed Mohammed 1, Vinod Kumar Goyal 1, Vijay Benade 1, Veera Raghava Chowdary Palacharla 1, Ramkumar Subramanian 1, Renny Abraham 1, Pradeep Jayarajan 1, Jyothsna Ravula 1, Satish Jetta 1
Suven Life Sciences Ltd - Hyderabad (India)

THEME
Clinical trials: cognitive and functional endpoints

RP4 Improving Screening Efficiency Through Alternate Story Recall
Thomas Doherty 1, Robert Smith 2, Michael Smith 3, Shau-Yu Lynch 4, Jeri Morris 4, Chad Swanson 4
1Worldwide Clinical Trials - London, England (United Kingdom), 2Worldwide Clinical Trials - Canet, France (United Kingdom), 3Worldwide Clinical Trials - Charlotte, Nc (United Kingdom), 4Eisai Inc. - Woodcliff Lake, Nj (USA), 5Roosevelt University Chiacgo - Chiacgo, Il (USA)

P6 Natural Disease Progression Model of Alzheimer’s Disease Using the Integrated Alzheimer’s
Brian Willis 1, Alette Wessels 1, Laiyi Chua 1, Kay Chow 1, Emmanuel Chigutsa 1, John Sims 1, Ivelina Gueorguieva 1
Eli Lilly And Company - Indianapolis (USA)

THEME
Clinical trials: imaging

RP5 Comparison of CT and MRI based standardized uptake value ratio for the amyloid PET analysis in subjective cognitive decline and mild cognitive impairment subjects
Dong Won Yang 1, Yun Jeong Hong 1, Junghhee Cho 1, Young Chul Youn 1
Department Of Neurology, College Of Medicine, The Catholic University Of Korea - Seoul (Korea, Republic of)

RP6bis Associations of Stages of Objective Memory Impairment (SOMI) with Alzheimer’s Disease Biomarkers in the A4 Study
Ellen Grober 1, Richard Lipton 1, Reisa Sperling 1, Keith Johnson 2, Dorene Rentz 2, Kathryn Papp 2, Paul Aisen 3, Ali Ezzati 1
1Albert Einstein College Of Medicine - Bronx (United States), 2Harvard Medical School - Boston (United States), 3University Of Southern California - San Diego (United States)
### POSTERS presented remotely

<table>
<thead>
<tr>
<th>P18</th>
<th>Mild behavioral impairment correlates of cognitive impairments in older adults without dementia: Mediation by amyloid pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yan Sun 1, Jintai Yu 2, Lan Tan 3</td>
<td>1Department Of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China - Qingdao (China), 2Department Of Neurology And Institute Of Neurology, Huashan Hospital, State Key Laboratory Of Medical Neurobiology And Moy Frontiers Center For Brain Science, Shanghai Medical College, Fudan University, Shanghai, China - Shanghai (China), 3Department Of Neurology And Institute Of Neurology, Huashan Hospital, State Key Laboratory Of Medical Neurobiology And Moy Frontiers Center For Brain Science, Shanghai Medical College, Fudan University, Shanghai, China - Qingdao (China)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LRP1bis</th>
<th>Six Recurrent Amyloid Related Imaging Abnormality Episodes in a Patient Treated with Aducanumab BV 2 J72</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jacob Hall 1, Elizabeth Mormino 1, Amanda Ng 1, Athanasia Boumis 1, Jennifer Gaudioso 1, Guido Davidson 1, Sharon Sha 2</td>
<td>1The Neurology Center Of Southern California - Temecula (United States), 2Department Of Neurology And Neurological Sciences, Stanford University - Stanford (United States), 3Stanford Center For Clinical Research, Stanford University - Stanford (United States), 4Global Alzheimer’s Platform Foundation - San Francisco (United States), 5Division Of Nuclear Medicine &amp; Molecular Imaging, Department Of Radiology, Stanford University - Stanford (United States)</td>
</tr>
</tbody>
</table>

### THEME: Clinical trials: biomarkers including plasma

<table>
<thead>
<tr>
<th>RP7</th>
<th>Levels of circulating memory CD8 T cells that induce AD-like pathology in mice correlate with cognition and decreased CSF Abeta42 in patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Wheeler 1, 2, Debby Van Dam 3, 4, Yannick Vermeiren 3, 4, Hans De Reu 1, Peter Paul De Deyn 3, 4, Vicky Yamamoto 1, 2</td>
<td>1T-Neuro Pharma, Inc. - Apsos (USA), 2Brain Mapping Fndn. - Pacific Palisades (USA), 3University Of Antwerp - Antwerp (Belgium), 4University Of Groningen - Groningen (Netherlands), 5University Of Southern California - Los Angeles (USA)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RP8</th>
<th>Serum Inflammatory biomarkers in Mild vs Moderate patients undergoing therapeutic plasma exchange with albumin replacement as a treatment for Alzheimer’s disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ana María Ortiz 1, Carla Minguet 1, Ricardo Gonzalo 1, Laura Núñez 1, Agustín Ruiz 2, 3, Oscar L López 4, Mercè Boada 2, 4, Antonio Páez 1, Montserrat Costa 1</td>
<td>1grifols Bioscience Research - Barcelona (Spain), 2research Center And Memory Clinic, Fundació ACE, Institut Català De Neurociències Aplicades-Universitat Internacional De Catalunya - Barcelona (Spain), 3Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III - Madrid (Spain), 4Division Of Nuclear Medicine &amp; Molecular Imaging, Department Of Radiology, Stanford University - Stanford (United States)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RP9</th>
<th>A polygenic risk score is associated with Alzheimer’s brain pathology in an age-dependent manner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Quinn 1, Chao-Yi Wu 1, Sahi Kolli 2, Nora Mattek 3, Randall Woltjer 2, Shawn Westaway 3, Jeffrey Kaye 3, Kelly Bakulski 4, Hiroko Dodge 4</td>
<td>1Department Of Neurology, Layton Aging And Alzheimer’s Disease Center, Oregon Health &amp; Science University - Portland (USA), 2International Business Machines (ibm) - New York (USA), 3Department Of Neurology, Layton Aging And Alzheimer’s Disease Center, Oregon Health &amp; Science University - Portland, Or (USA), 4Department Of Epidemiology At The University Of Michigan School Of Public Health And Michigan Alzheimer’s Disease Center - Ann Arbor (USA)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RP10</th>
<th>Longitudinal Tau Accumulation in Alzheimer’s disease: Prospective 5-year follow-up study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hanna Cho 1, Min Seok Baek 3, Han Kyel Kim 1, Jae Hoon Lee 3, Jong Hoon Ryu 3, Chul Hyoung Lyoo 1</td>
<td>1Department Of Neurology, Gangnam Severance Hospital, Yonsei University College Of Medicine - Seoul (Korea, Republic of), 2Department Of Neurology, Yonsei University College Of Medicine - Seoul (Korea, Republic of), 3Department Of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College Of Medicine - Seoul (Korea, Republic of), 4Department Of Nuclear Medicine, Severance Hospital, Yonsei University College Of Medicine - Seoul (Korea, Republic of)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RP11</th>
<th>Assessment of High Risk for Alzheimer’s Disease Using Plasma Biomarkers in Subjects with Normal Cognition in Taiwan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shieh-Yueh Yang 1</td>
<td>1Magqu Co., Ltd. - New Taipei City (Taiwan, Province of China)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RP12</th>
<th>Evidence of plasma biomarkers for high risk of dementia in cognitively normal subjects of post stroke, family history of Alzheimer’s disease, diabetes mellitus, end-stage renal disease and obstructive sleep apnea</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shieh-Yueh Yang 1</td>
<td>1Magqu Co., Ltd. - New Taipei City (Taiwan, Province of China)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RP13</th>
<th>Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: The CABLE study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lingzhi Ma 1</td>
<td>1Department Of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China (China)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RP13bis</th>
<th>Cerebrospinal fluid platelet-derived growth factor receptor-β measured in BioFINDER 2: a marker of microvascular damage?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Claudia Cicognola 1, 2, Shorena Janelidze 1, Danielle Van Westen 3, 4, Khazar Ahmadi 1, Oskar Hansson 1, 2</td>
<td>1Clinical Memory Research Unit, Lund University (Sweden), 2Memory Clinic, Skåne University Hospital (Sweden), 3Diagnostic Radiology, Department Of Clinical Sciences Lund, Lund University (Sweden), 4Image and Function, Skåne University Hospital, Malmö (Sweden)</td>
</tr>
</tbody>
</table>
**POSTERS presented remotely**

**P21** Plasma Neurofilament Light and Longitudinal Progression of White Matter Hyperintensity in Elderly Persons Without Dementia
Yan Sun 1, Jintai Yu 2, Lan Tan 1
1Department Of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China - Qingdao (China), 2Department Of Neurology And Institute Of Neurology, Huashan hospital, Fudan University, Shanghai, China - Shanghai (China), 3Department Of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China - Qingdao (China)

**LRP3** Pre-analytics of the Aβ42/Aβ40 ratio in fresh and frozen samples using an optimized CSF collection protocol
Rianne Esquivel 1, Sara Ho 2, Jacqueline Darrow 1, Amanda Calabro 1, Sara Gannon 1, Parmi Thakker 1, Francesca De Simone 1, Abhay Moghekar 2
1Fujirebio Diagnostics Inc - Malvern (United States), 2Johns Hopkins School Of Medicine - Baltimore (United States)

**LRP4** Pre-Analytical Effects of Cap Contact and Mixing on CSF Aβ42, Aβ40, and ptau181 Concentrations when Measured on an Automated Chemiluminescent Platform
Sara Ho 1, Francesca De Simone 2, Jacqueline Darrow 1, Amanda Calabro 1, Parmi Thakker 1, Sara Gannon 1, Rianne Esquivel 2, Abhay Moghekar 1
1Johns Hopkins School Of Medicine - Baltimore (United States), 2Fujirebio Diagnostics Inc - Malvern (United States)

**LRP5** Evaluate the Utility of Sapphire II Scanning Compared to Quantitative Beta Amyloid PET Scans in MCI and Mild AD Subjects
Lee Goldstein 1, Carl Sadowsky 2, Susanne Wilke 1, Suzanne Hendrix 4, Dennis Nilan 3
1Boston University, Boston (United States), 2Premier Neurology - West Palm Beach (United States), 3Cognoptix - Marlborough (United States), 4Pentara - Salt Lake City (United States)

**THEME: Clinical trials: methodology**

**RP14** The ADataViewer: Exploring Alzheimer’s Disease Cohort Data
Yasamin Salimi 1, 2, Daniel Domingo-Fernández 1, Carlos Bobis-Álvarez 1, Martin Hofmann-Apitius 1, 2, Colin Birkenbihl 1, 2
1Department Of Bioinformatics, Fraunhofer Institute For Algorithms And Scientific Computing (scai) - Sankt Augustin (Germany), 2Bonn-Aachen International Center for IT, Rheinische Friedrich-Wilhelms-Universität Bonn - Bonn (Germany), 3University Hospital Ntra. Sra. De Candelaria - Santa Cruz De Tenerife (Spain)

**RP15** What Might Intrinsic Changes in Screen to Baseline CDRs in Alzheimer’s Clinical Trials Signify: An Exploratory Analysis
Alan Kott 1, David Miller 2
1Signiant Health - Prague (Czech Republic), 2Signiant Health - Blue Bell (USA)

**RP15bis** Optimization of clinical trial design for combination therapies using virtual patients
Hugo Geerts 1, Mike Walker 2, Rachel Rose 2
1Certara - Berwyn, Pa (USA), 2Certara - Sheffield UK (United Kingdom)

**RP16** Evaluating the effectiveness of a digital therapeutic to reduce Alzheimer’s risk: A randomized controlled trial
Mark McInnis 1, Richard Isacsson 2, Robert Krikorian 3
1Retain Health - Bedford (USA), 2Alzheimer’s Disease Education Consultants - Miami Beach (USA), 3University Of Cincinnati Academic Health Center - Cincinnati (USA)

**RP17** Clinical Trial Protocol of Bromocriptine in Alzheimer’s Disease with Presenilin 1 (PSEN1) Mutations
Haruhiko Banno 1, Takayuki Kondo 1, Taro Okunomiya 1, Yoko Amino 1, Akiyoshi Nakakura 1, Ryuji Tada 1, Akihiro Shindo 2, Takakuni Maki 1, Manabu Ikeda 1, Yuishin Izumi 1, Kazutoki Kanemaru 1, Kenji Ishii 3, Kazue Shigenobu 1, Yoshichi Sunada 1, Toshifumi Watanabe 1, Osamu Uchikawa 1, Ryosuke Takahashi 1, Hidekazu Tomimoto 2, Haruhisa Inoue 1
1Kyoto University - Kyoto (Japan), 2Mie University - Tsu (Japan), 3Osaka University - Suita (Japan), 4Tokushima University - Tokushima (Japan), 5Tokyo Metropolitan Geriatric Medical Center - Tokyo (Japan), 6Tokyo Metropolitan Institute Of Gerontology - Tokyo (Japan), 7Osakayama Hospital - Sakai (Japan), 8Kawasaki Medical School - Kurashiki (Japan), 9Time Therapeutics, Inc. - Kyoto (Japan), 10Towa Pharmaceutical Co., Ltd. - Osaka (Japan)

**P29** Effects of Exclusion Criteria on Disease Modifying Clinical Trials for Alzheimer’s Disease
Aaron Ritter 1, Joel Adu-Brimpong 1, Marwan Sabbagh 1, Jiong Shi 1, Justin Miller 1, Jessica Caldwell 1
1Cleveland Clinic - Las Vegas (USA)

**LRP6** Impact of gender on the willingness to consider participating in clinical trials and undergo a lumbar puncture in middle aged individuals at risk of Alzheimer’s disease
Lidia Canals-Gispert 1, Alba Cañas-Martínez 1, Gema Huesa 1, Marc Suárez-Calvet 1, 2, 3, Marta Milà-Alomà 1, 2, 3, Eider Arenaza-Urgujo 1, 2, 3, Davide Cirillo 4, Annemarie Schumacher Dimech 4, 5, Maria Florencia Iulita 4, 6, Julie Martinikova 7, 8, Maria Carmela Tartaglia 4, Gonzalo Sánchez-Benavides 1, 2, 3, Carolina Mingullon 1, 2, 3, Karine Fauria 1, 2, 3, Maria Teresa Ferretti 4, 5, Anna Brugulat-Serrat 1, 2, 3
1Barcelonabeta Brain Research Center - Barcelona (Spain), 2IMIM (Hospital del Mar Medical Research Institute) - Barcelona (Spain), 3Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) - Madrid (Spain), 4Women’s Brain Project - Guntershausen (Switzerland), 5Department of Health Sciences and Medicine, University of Lucerne - Lucerne (Switzerland), 6Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona - Barcelona (Spain), 7Cognitive Center, Department Of Neurology, Second Faculty Of Medicine, Charles University, And Motol University Hospital - Prague (Czech Republic)

**CTAD 2021**
**POSTERS presented remotely**

**LRP7**  
*QyPredict®: added value to patient selection strategies and statistical analysis in clinical trials on Alzheimer’s Disease*
  
Jorge Samper-González 1, Marwan Sabbagh 2, Philippe Scheltens 3, Elizabeth Gordon 4, Antoine Movschein 5, Nicolas Guizard 6, Clarisse Longo Dos Santos 7, Enrica Cavedo 8, Alireza Atri 9, Bruno Dubois 10  
1Dyneaple - Paris (France), 2Cleveland Clinic Lou Ruvo Center For Brain Health - Las Vegas, NV (United States), 3Amsterdam University Medical Center - Amsterdam (Netherlands), 4Banner Sun Health Research Institute, Banner Health - Sun City, AZ (United States), 5Brigham and Women’s Hospital, Harvard Medical School - Boston, MA (United States), 6Institute Of Memory And Alzheimer’s Disease (im2a), Centre Of Excellence Of Neurodegenerative Disease (coen), Icm, Ctr Neuroscience, Ap-Hp, Department Of Neurology, Hôpital De La Pitié-Salpêtrière, Sorbonne University - Paris (France)

**LRP8**  
*A Fully Virtual Trial Design in Times of COVID-19: Early Lessons Learned from the REACTION study in Age-Related Cognitive Decline*
  
Christian Camargo 1, Katalina Mcinerney 2, Danielle Coutonnette 3, Tatjana Rundek 4  
1University Of Miami Miller School Of Medicine - Miami (United States), 2Danone Nutricia Research - Utrecht (Netherlands)

**LRP9**  
*An assessment of the statistical reliability of data-driven decomposition for the use of multi-modal analyses*
  
Kristen Knight 1, 2, Nicole Lazar 3, Liang Liu 4  
1UCSF Department of Radiology and Biomedical Imaging - San Francisco, CA (United States), 2VA Advanced Imaging Research Center, San Francisco Veteran’s Administration Medical Center - San Francisco, CA (United States), 3PennState Department of Statistics - University Park, PA (United States), 4UGA Department of Statistics - Athens, GA (United States)

**THEME**  
Clinical trials: results

**RP18**  
*Fortasyn Connect’s long-term intervention effects on Clinical Dementia Rating – sum of boxes and on memory in the LipiDiDiet RCT*
  
Tobias Hartmann 1, 2, Alina Solomon 3, 4, 5, Pieter Visser 6, 7, Suzanne Hendrikx 8, Kaj Bliennow 9, 10, Miia Kiviplet 11, 12, Hilka Sohtmann 13  
1Deutsches Institut Für Demenz Prävention (dipd), Medical Faculty, Saarland University - Homburg (Germany), 2Department of Experimental Neurology, Saarland University - Homburg (Germany), 3Department Of Neurology, Institute Of Clinical Medicine, University Of Eastern Finland - Kuopio (Finland), 4Department of Clinical Geniatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Huddinge (Sweden), 5Clinical Trials Unit, Theme Aging, Karolinska University Hospital - Huddinge (Sweden), 6Department Of Psychiatry And Neuropsychiatry, Alzheimer Centre Limburg, University Of Maastricht - Maastricht (Netherlands), 7Department of Neurology, Alzheimer Centre, Amsterdam Neuroscience, VU University Medical Centre - Amsterdam (Netherlands), 8Pentara Corporation - Millcreek (USA), 9Department Of Psychiatry-And Neurochemistry, Institute Of Neuroscience And Physiology, The Sahlgrenska Academy At University Of Gothenburg - Mölndal (Sweden), 10Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), 11Neurocentre, Department of Neurology, Kuopio University Hospital - Kuopio (Finland)

**RP19**  
*Validation of exposure-dependent activity on cognitive and functional decline confirms hydromethylthionine as a potential near-term oral treatment for Alzheimer’s disease (AD)*
  
Claude Wischik 1, 2, Helen Shells 1, Bjorn Schelter 1, 2  
1Taurx Therapeutics Ltd - Aberdeen (United Kingdom), 2University of Aberdeen - Aberdeen (United Kingdom)

**P41**  
*Single and multiple ascending dose studies in healthy volunteers to assess the safety and PK of LY3372689, an inhibitor of the O-GlcNAcase (OGA) enzyme*
  
Paul Goldsmith 1, Stephen Lowe 1, Krista Phipps 1, Kevin Donnelly 1, Kevin Biglan 1, Michele Mancini 1, Hugh Nuthall 1, Dustin J. Mergott 1, William Kielbasa 1  
1Eli Lilly And Company, Lilly Corporate Center - Indianapolis (USA)

**P43bis**  
*Brain target occupancy of LY3372689, an inhibitor of the O-GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteers*
  
William Kielbasa 1, Sergey Shcherbinin 1, Paul Goldsmith 1, Krista M. Phipps 1, Kevin Biglan 1, Michele Mancini 1, David Russell 2, Cristian Constantinescu 2, Roger N. Gunn 3, Hugh N. Nuthall 1, Dustin J. Mergott 1, Stephen Lowe 1, Emily C. Collins 1  
1Eli Lilly And Company, Lilly Corporate Center - Indianapolis (USA), 2University of Aberdeen - Aberdeen (United Kingdom)

**P44**  
*ACI-24, an anti-beta amyloid vaccine, in patients with mild Alzheimer’s disease: Results of a phase 2, randomized, double-blind, placebo-controlled study*
  
Olivier Sol 1, 2, Saskia Delpretti 1, Marija Vukcevic 1, Merja Hallikainen 2, Roy Jones 3, Anne Börjesson-Hanson 4, Aliya Asher 5, Alex Thompson 6, Christopher Kipps 7, Emer Mcsweeney 1, Tanja Touilloux 1, Julian Gray 1, Nicolas Fournier 1, Valérie Hliva 1, Antonio Melo Dos Santos 1, Mika Scheinin 9, 10, Marie Kosco-Vilbois 1, Johannes Streffer 11, Andrea Pfeifer 1, Juha Rinne 9, 10  
1Ac Immune Sa - Lausanne (Switzerland), 2University Of Eastern Finland - Kuopio (Finland), 3University Of Bath - Bath (United Kingdom), 4Karolinska University Hospital - Stockholm (Sweden), 5Macc Clinical Research - Manchester (United Kingdom), 6Macc Clinical Research - Cancnock (United Kingdom), 7Southampton General Hospital - Southampton (United Kingdom), 8Cognition Health Ltd. - Guildford (United Kingdom), 9University Of Turku - Turku (Finland), 10CRST Oy - Turku (Finland), 11Department of Biomedical Sciences, University of Antwerp- Antwerp (Belgium)

**LRP10**  
*Beneficial Effects of Masupirdine on Agitation in Patients with Alzheimer’s disease: A Novel Non-sedating Mechanism*
  
Ramakrishnna Nirgci 1, Anil Shinde 1, Abdul Rasheed Mohammed 1, Vinod Kumar Goyal 1, Santosh Kumar Pandey 1, Vijay Benade 1, Veera Raghava Chowdary Palacharla 1, Ramkumar Subramanian 1, Renny Abraham 1, Pradeep Jayarajan 1, Jyothsna Ravula 1, Satish Jetta 1  
1Suven Life Sciences Ltd - Hyderabad (India)
**POSTERS presented remotely**

** THEME**
Cognitive assessment and clinical trials

**RP16**
RetiSpec’s Hyperspectral Imaging System: Results of a Validation Study in Preclinical AD and MCI
Sharon Cohen 1, Arthur Plante 2, 4, 10, Alon Hazan 2, Adam Gribble 2, Yi Ping Lin 3, Justin Digregorio 3, Westreich Jared 3, Ian Cohen 1, Andriy Strichuk 1, Julie Soehner 1, Fred Leblond 4, 10, Michal Schnaider-Beeri 4
1Toronto Memory Program - Toronto (Canada), 2Retispec Inc. - Montréal (Canada), 3Department of Engineering Physics, Polytechnique Montreal - Montréal (Canada), 4Centre de recherche du Centre hospitalier de l’Université de Montréal - Montréal (Canada), 10Department Of Engineering Physics, Polytechnique Montreal, Montréal, Québec, Canada; Centre De Recherche Du Centre Hospitalier De L’université De Montréal - Montréal (Canada), 5Centre De Recherche Du Centre Hospitalier De L’université De Montréal - Montréal (Canada), 6The Joseph Sagol Neuroscience Center, Sheba Medical Center, Israel; Professor, Iahn School Of Medicine At Mount Sinai - Tel Hashomer (Israel)

**RP20**
Association between a computerized, self-administered cognitive assessment and fluid biomarkers of neurodegeneration
Mina Aghaie 1, Mohammad Hadi Modarres 1, Zahra Yahab 1, 2, 3, Chris Kalafatis 1, 2, 3, Haniye Marefat 4, Mahdieh Khanbazi 5, Hamed Karimi 5, 6, 7, Seyed-Mahdi Khaligh-Razavi 1, 2
1Royan Institute For Stem Cell Biology And Technology, Acce - Tehran (Iran, Islamic Republic of), 2Cognitivy Ltd - London (United Kingdom), 3Department Of Geriatric Medicine, Ziaei Hospital, Tehran University Of Medical Sciences - Tehran (Iran, Islamic Republic of), 4Memory and Behavioral Neurology Division, Roozbeh Hospital, Tehran University Of Medical Sciences - Tehran (Iran, Islamic Republic of), 5South London & Maudsley NHS Foundation Trust - London (United Kingdom), 6Department of Old Age Psychiatry, King’s College London - London (United Kingdom), 7School Of Cognitive Sciences, Institute For Research In Fundamental Sciences (ipm) - Tehran (Iran, Islamic Republic of), 8Department Of Mathematics And Computer Science, Amirkabir University Of Technology - Tehran (Iran, Islamic Republic of)

**RP21**
The development of ObsRVR: an Observational Instrument to measure Reactions of People with Dementia Experiencing Virtual Reality
Lora Appel 1, Erika Kisonas 2, Eva Appel 3
1York University - Toronto (Canada), 2University Health Network - Toronto (Canada)

**RP22**
Psychometric validation of the Brief And Simple Index of Cognition (BASIC) and sensitivity to cognitive impairment in individuals living with MCI and Alzheimer’s disease
Anna Barzczak 1, Sebastian Harrison 2, Ninoslav Mimica 3, John Harrison 4
1Mossakowski Medical Research Centre - Warszawa (Poland), 2Manchester Metropolitan University - Manchester (United Kingdom), 3University Psychiatric Hospital Vrapce - Zagreb (Croatia), 4Metis Cognition Ltd - Kilmington (United Kingdom)

**RP23**
Tau pathologies mediate the association of blood pressure with cognitive impairment in adults without dementia: The CABLE study
Hu Hao 1, Tan Lan 1, Yu Jin-Tai 2
1Qingdao University - Qingdao (China), 2Fudan University - Shanghai (China)

**RP24**
Identification of novel drug targets for Alzheimer’s disease by integrating genetics and proteomes from brain and blood
Jin-Tai Yu 1
Department Of Neurology And Institute Of Neurology, Huashan Hospital, State Key Laboratory Of Medical Neurobiology And Moe Frontier Center For Brain Science, Shanghai Medical College, Fudan University - Shanghai (China)

**RP25**
Sigmoid methodology allows early prediction of cognitive decline towards Alzheimer’s disease across several cognitive domains
Marcela Cespedes 1, Cai Gills 1, Paul Maruff 2, 3, Nancy Maserejian 1, Chris Fowler 3, Stephanie Rainey-Smith 3, 4, Victor Villemagne 3, 9, Christopher Rowe 3, 10, Ralph Martins 5, 6, 9, 10, Colin Masters 5, James Doecke 1
1Australian E-Health Research Centre, Csiro - Herston, Old (Australia), 2Biogen - Cambridge, Ma (USA), 3Cogstate Pty. Ltd - New Haven, Ct (USA), 4University of Melbourne - Parkville, Vic (Australia), 5The Florey Institute Of Neuroscience And Mental Health, University Of Melbourne - Parkville, Vic (Australia), 6Centre For Healthy Ageing, Health Futures Institute, Murdoch University - Murdoch, Western Australia (Australia), 7Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University - Joondalup, Western Australia (Australia), 8Department Of Molecular Imaging And Therapy, Austin Health - Heidelberg, Victoria (Australia), 9Department of Psychiatry, The University of Pittsburgh - Pittsburgh, Pa (USA), 10Department of Biomedical Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University - Sydney, New South Wales (Australia), 11Sir James McCusker Alzheimer’s Disease Research Unit (Hollywood Private Hospital) - Perth, Western Australia (Australia)

**P51**
Quick Dementia Rating System and its relationship to neuropsychological scores and biomarkers
Kevin Duff 1, Deborah Levine 2, Bruno Giordani 2, Angi Fagerlin 1, Nicole Fowler 2, John Hoffman 1
1University Of Utah - Salt Lake City, Ut (USA), 2University Of Michigan - Ann Arbor, Mi (USA), 3Indiana University - Bloomington, In (USA)

**P52**
Can scores on the Repeatable Battery for the Assessment of Neuropsychological Status predict amyloid deposition?
Kevin Duff 1, Kayla Suhrrie 1, Dustin Hammers 2, Ava Dixon 1, John Hoffman 1
1University Of Utah (USA), 2University Of Utah (USA)

**P55**
Evaluation relationships between subjective wellbeing, personality traits, and Alzheimer’s disease: A two-sample Mendelian randomization study
Ya-Hui Ma 1, Yu-Xiang Yang 2, Qiang Dong 3, Lan Tan 1, Jin-Tai Yu 2
1Qingdao Municipal Hospital, College Of Clinical Medicine, Qingdao University - Qingdao (China), 2Fudan University - Shanghai (China), 3Qingdao Municipal Hospital, College Of Clinical Medicine, Qingdao University - Shanghai (China)
Serum uric acid may aggravate Alzheimer's disease risk by affecting amyloidosis in cognitively intact older adults: The CABLE study

Lin-Lin Li 1, Ya-Hui Ma 1, Jin-Tai Yu 2
1Dalian Medical University - Dalian (China), 2Qingdao Municipal Hospital, College of Clinical Medicine, Qingdao University - Qingdao (China)

Metabolically healthy obesity and lipids may be protective factors for pathological changes of Alzheimer's disease in cognitively normal adults

Shu-Juan Huang 1, Ya-Hui Ma 1, Lan Tan 1, Jin-Tai Yu 2
1Qingdao Municipal Hospital, College of Clinical Medicine, Qingdao University - Qingdao (China), 2Fudan University - Shanghai (China)

Association of body mass index with risk of cognitive impairment and dementia: A systematic review and meta-analysis of prospective studies

Yi Ou 1, Lan Tan 1, Jin-Tai Yu 2
1Department Of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China - Qingdao (China), 2Department Of Neurology And Institute Of Neurology, Huashan hospital, Shanghai Medical College, Fudan University, Shanghai, China - Shanghai (China)

Modifiable Risk Factors for Incident Dementia and Cognitive Impairment: An Umbrella Review of Evidence

Jin-Tai Yu 1
Department Of Neurology and Institute Of Neurology, Huashan Hospital, State Key Laboratory Of Medical Neurobiology And Moe Frontiers Center For Brain Science, Shanghai Medical College, Fudan University - Shanghai (China)

Global prevalence of Alzheimer's disease across disease stages

Anders Gustavsson 1, Nicholas Norton 2, Thomas Fast 2, Lutz Frölich 2, Drew Holzapfel 4, Tunahan Kirabali 5, Pierre Krolak-Salmon 6, Paolo Maria Rossini 7, Lydia Lanman 8, Antonella Santuccione Chadha 9, Wiesje M. Van Der Flier 9
1Quantify Research; Department Of Neurobiology, Care Sciences And Society, Karolinska Institute - Stockholm (Sweden), 2Quantify Research - Stockholm (Sweden), 3Department Of Geriatric Psychiatry, Central Institute Of Mental Health Medical Faculty Mannheim, University Of Heidelberg - Mannheim (Germany), 4Ceo Initiative On Alzheimer's Disease - Philadelphia (USA), 5Biogen - Baar (Switzerland), 6Lyon Institute For Elderly, Clinical & Research Memory Center Of Lyon - Lyon (France), 7Faculty Of Medicine Of The Catholic University Of The Sacred Heart, Neuroscience Area Of Polliclinico Foundation A. Gemelli - Rome (Italy), 8F. Hoffmann-La Roche - Basel (Switzerland), 9Alzheimer Center Amsterdam, Department Of Neurology, Department Of Epidemiology And Data Science, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam Umc - Amsterdam (Netherlands)

Association between Widespread Pain and Dementia, Alzheimer's disease and Stroke: A Cohort Study from the Framingham Heart Study

Kanran Wang 1
The First Affiliated Hospital of Chongqing Medical University - Chongqing (China)

Genetically determined blood pressure, antihypertensive medications, and risk of Alzheimer’s disease: a Mendelian randomization study

Ya-Nan Ou 1, Lan Tan 1, Jin-Tai Yu 2
1Department Of Neurology, Qingdao Municipal Hospital, Qingdao University - Qingdao (China), 2Department Of Neurology And Institute Of Neurology, Who Collaborating Center For Research And Training In Neurosciences, Huashan Hospital, Shanghai Medical College, Fudan University - Shanghai (China)

Social Networks and Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Pathology in Cognitively Intact Older Adults: The CABLE Study

Ya-Hui Ma 1, Ya-Yu Wang 2, Lan Tan 3, Jin-Tai Yu 4
1Qingdao Municipal Hospital, College of Clinical Medicine, Qingdao University - Qingdao (China), 2Qingdao Municipal Hospital, College of Clinical Medicine, Dalian Medical University - Dalian (China), 3Qingdao Municipal Hospital, College of Clinical Medicine, Dalian Medical University - Qingdao (China), 4Fudan University - Shanghai (China)

Evaluation of efficaciy and cost-effectiveness of promotions for recruiting online participants to Japanese Trial-Ready Cohort (J-TRC) study

Kenichiro Sato 1, Yoshiki Niimi 2, Ryoko Ibara 1, Kazushi Suzuki 3, Atsushi Iwata 4, Takeshi Iwatsubo 1
1University Of Tokyo - Bunkyo City (Japan), 2University Of Tokyo Hospital - Bunkyo City (Japan), 3Tokyo Metropolitan Geriatric Medical Center Hospital - Itabashi City (Japan), 4National Defense Medical College - Tokorozawa City (Japan)

Decision-Making and Reactions on Genetic Testing in Alzheimer's Disease among Patients, Caregivers, and Healthcare Professionals

Amir Tahami 1, Stephen Doogan 2, Nardin Farid 2, Margaret Bray 1, Esra Karahan 1, Ouanwu Zhang 1
1Eisai - Woodcliff Lake, NJ (USA), 2Real Life Sciences - King Of Prussia, PA (USA)

Amyloid Prediction in Early-Stage Alzheimer’s Disease From Acoustic and Linguistic Patterns of Speech: design of the AMYPRED studies

Emil Fristed 1, Marton Meszaros 1, Caroline Skirrow 1, Jack Weston 1
Novoic - London (United Kingdom)

A Multi-modal Curriculum on Dementia-related Psychosis for the Public: A Randomized Trial

Nabeel Saif 1, Kellyann Niotis 1, Ciara Gaglio 1, Richard Isaacson 1
Weill Cornell Medicine - New York (USA)
RP30  Comparison of the accuracy of Cogniciti’s self-administered, online, Brain Health Assessment to the Montreal Cognitive Assessment in detecting amnestic mild cognitive impairment  
Theone Paterson 1,2, Brintha Sivajohan 1, Sandra Gardner 1, Malcolm Binns 5, Kathryn Stokes 2, Morris Freedman 6,2, Brian Levine 5,4, Angela Troyer 2  
1University Of Victoria - Victoria (Canada), 2Baycrest Health Sciences Centre - Toronto (Canada), 3Western University - London (Canada), 4Baycrest Health Sciences Centre - Toronto (Canada), 5Rotman Research Institute - Toronto (Canada), 6Baycrest Health Sciences Centre-Toronto (canada) - Toronto (Canada), 7Toronto Dementia Research Alliance - Toronto (Canada), 8University of Toronto - Toronto (Canada)

RP31  “ComuniChiAmo”: an e-Health pilot study for the development of a community support network for carers of people with dementia  
Cristina Festari 1, Stefania Orini 2, Anna Mega 1, Cristina Muscio 1, Pietro Traboschi 3, Marco Trabucchi 3, Orazio Zanetti 2, Rabih Chattat 4  
1Laboratory Of Alzheimer's Neuroimaging And Epidemiology At The Istituto Centro San Giovanni Di Dio Fatebenefratelli (Italy) - Brescia (Italy), 2Irccs Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia, Italy - Brescia (Italy), 3Neurology 5-Neuropathology Unit, Fondazione Ircss Istituto Neurologico Carlo Besta, Italy - Milan (Italy), 4Department Of Pharmacology, For Vergata University, Rome, Italy - Rome (Italy), 5Associazione Italiana di Psicogeriatría, Brescia, Italy - Brescia (Italy), 6Department Of Psychology, University Of Bologna, Bologna, Italy - Bologna (Italy)

RP32  VRCT: Randomized Controlled Trial Evaluating the Impact of Virtual Reality-therapy on BPSD and QoL of Acute Care In-patients With Dementia  
Lora Appel 1, Eva Appel 2, Erika Kisonas 2, Jarred Rosenberg 3, Julian Appel 4, Christopher Smith 3  
1York University - Toronto (Canada), 2University Health Network - Toronto (Canada), 3Michael Garron Hospital - Toronto (Canada), 4Ryerson University - Toronto (Canada)

LP12  Remote actigraphy measurement with a simple-to-use wearable device: Feasibility and compliance in older adults with and without subjective cognitive decline  
Michael Kraus 1, Alexandra Atkins 1, William Horan 1, Heather Stevens 1, Erica Walton 1, Joshua Yuan 1, Matthew Welch 1, Haley Evans 1, Richard Keefe 1  
Verasci - Durham (United States)

LP13  A Machine Learning Based Multi-modal Imaging Genetic Study to Predict Future Progression and Conversion to Alzheimer’s Disease  
Ghazal Mirabnehrazam 1, Da Ma 1, Siew Lee 1,2, Karteek Popuri 1, Hyunwoo Lee 1, Jiguo Cao 1, Lei Wang 1, James E Galvin 1, Mirza Faisal Beg 1  
1Simon Fraser University - Burnaby (Canada), 2University Of Nottingham - Nottingham (United Kingdom), 3University Of British Columbia - Vancouver (Canada), 4Ohio State University Wexner Medical Center - Columbus (United States), 5University Of Miami Miller School Of Medicine - Miami (United States)

THEME  Health economics and clinical trials

RP33  Using ARIA to detect cognitive normal subjects with high burden WMH for early prevention clinical trials of dementia – suggestions based on a simulation trial  
Jianlin Liang  
Chinese University of Hong Kong, Hong Kong (China)

LP11  Impact of physical activity on cognitive decline in adults: A FLAME analysis in the PROTECT cohort  
Helen Brooker 1, Vincent Hayman 1, Dag Aarsland 2, Byron Creese 1, Clive Ballard 1, Anne Corbett 1  
1Exeter University Medical School - Exeter (United Kingdom), 2Department Of Old Age Psychiatry, Institute Of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King’s College London, London, London UK - London (United Kingdom)

THEME  New therapies and clinical trials

RP39  Alpha-1 antitrypsin variants and obstructive sleep apnea: practical targets for modulating inflammation and altering trajectory of MCI/dementia  
Donald Schmechel 1  
Acrossalpha; Neurology Specialists Of Charleston - Burnsville

RP40  A randomized, placebo-controlled, double-blind, single ascending dose study to evaluate the safety, tolerability and pharmacokinetics of a subcommissural organ-spondin-derived peptide in healthy volunteers  
Valérie Bourdès 1, Peter Dogterom 2, Pierre Parmantier 3, Damien Colas 1, Sighild Lemarchant 1, Sébastien Marie 1, Khalid Abd-Elaziz 2, Yann Godfrin 4  
1Axolitis - Lyon (France), 2OPS Netherlands B.V - Groningen (Netherlands), 3Athena Bio Consulting - Lyon (France), 4Godfrin Life Sciences - Caluire-et-Cuire (France)

RP41  Microdose Study of a Novel Psychostimulant Prodrug, PRX-P4-003, with Reduced Abuse Liability for Apathy in AD  
William Ziegler Potter 1, Valentino Stella 1,2, Sandeep Patil 1  
1Praxis Bioresearch - Sacramento (USA), 2University of Kansas - Lawrence (USA)
PROOF OF CONCEPT/TRANSLATIONAL RESEARCH FOR ALZHEIMER DRUG DEVELOPMENT INTERVENTIONS

RP42  Inhibition of the equilibrative nucleoside transporter 1 (ENT1) rescues cognitive impairment and misfolded protein accumulation in two mouse models with distinct features of Alzheimer’s disease pathology
Ching-Pang Chang 1,2, Chien-Yu Lin 1,2, Kuo-Chen Wu 2, Hsin-Hsien Yeh 3, Chun-Jung Lin 4, Yijuang Chern 1,2
1Institute of Biomedical Sciences, Academia Sinica - Taipei (Taiwan, Province of China), 2Biomedical Translation Research Center, Academia Sinica - Taipei (Taiwan, Province of China), 3Brain Research Center, National Yang Ming Chiao Tung University - Taipei (Taiwan, Province of China), 4School Of Pharmacy, National Taiwan University - Taipei (Taiwan, Province of China)

RP43  Targeting microRNA-485-3p blocks Alzheimer’s disease progression
Hanseo Koh 1, Sangjoon Lee 2, Hyojin Lee 1, Jaewoong Min 1, Takeshi Iwatsubo 3, Charlotte Teunissen 4, Hyunjeong Cho 5, Jinhyeob Ryu 6
1Biorchestra Co., Ltd. - Daejeon (Korea, Republic of), 2University Of Tsukuba - Ibaraki (Japan), 3University Of Tokyo - Tokyo (Japan), 4Amsterdam Umc, VU University - Amsterdam (Netherlands), 5College Of Medical Science, Konyang University - Daejeon (Korea, Republic of), 6Biorchestra Co., Ltd. - Boston (USA)

LRP14  Investigating potential druggability of long non-coding RNAs for novel treatment of Alzheimer’s Disease
Yuji Zhang 1, Cui Tao 2
1University Of Maryland Baltimore - Baltimore (United States), 2University Of Texas Health Science Center - Houston (United States)